The secreted serine protease xHtrA1 is a positive feedback regulator of long-range FGF signaling

PhD Thesis

in partial fulfillment of the requirements for the degree “Doctor of Philosophy (PhD)” in the Molecular Biology Program at the Georg August University Göttingen, Faculty of Biology

submitted by

Shirui Hou

born in

Beijing, P. R. China

June, 2007
Affidavit

Herewith I declare, that I prepared the PhD thesis
“The secreted serine protease xHtrA1 is a positive feedback regulator
of long-range FGF signaling ”
on my own and with no other sources and aids than quoted.

Shirui Hou

Date of submission June, 2007
List of Publications


2. Hou S., Maccarana M., Min T. H., Strate I., Pera E. M. The secreted serine protease xHtrA1 is a positive feedback regulator of long-range FGF signaling (accepted for publication in *Dev. Cell*).
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table of Contents</td>
<td>I</td>
</tr>
<tr>
<td>Acknowledgments</td>
<td>IV</td>
</tr>
<tr>
<td>Abstract</td>
<td>VI</td>
</tr>
<tr>
<td>List of Figures</td>
<td>VII</td>
</tr>
<tr>
<td>Abbreviations</td>
<td>VIII</td>
</tr>
<tr>
<td>**1. **INTRODUCTION</td>
<td></td>
</tr>
<tr>
<td>1.1 <em>Xenopus laevis</em> as model system for developmental biology</td>
<td>1</td>
</tr>
<tr>
<td>1.2 The breakage of symmetry in <em>Xenopus</em> embryos</td>
<td>1</td>
</tr>
<tr>
<td>1.3 Mesoderm induction during embryogenesis</td>
<td>2</td>
</tr>
<tr>
<td>1.4 The formation of the Spemann-Mangold organizer</td>
<td>4</td>
</tr>
<tr>
<td>1.5 The default model of neural induction</td>
<td>5</td>
</tr>
<tr>
<td>1.6 Other signals involved in neuralization</td>
<td>7</td>
</tr>
<tr>
<td>1.7 Regional specification of the central nervous system</td>
<td>9</td>
</tr>
<tr>
<td>1.8 Fibroblast growth factor signaling</td>
<td>10</td>
</tr>
<tr>
<td>1.9 FGFs in mesoderm induction</td>
<td>10</td>
</tr>
<tr>
<td>1.10 FGFs in neural induction</td>
<td>11</td>
</tr>
<tr>
<td>1.11 FGFs in posterior development</td>
<td>13</td>
</tr>
<tr>
<td>1.12 Proteoglycans as regulators of FGF signaling</td>
<td>13</td>
</tr>
<tr>
<td>1.13 HtrA superfamily</td>
<td>14</td>
</tr>
<tr>
<td>1.14 Aim of the study</td>
<td>15</td>
</tr>
<tr>
<td>**2. **MATERIALS AND METHODS</td>
<td></td>
</tr>
<tr>
<td>2.1 Materials</td>
<td>16</td>
</tr>
<tr>
<td>2.1.1 Solutions</td>
<td>16</td>
</tr>
<tr>
<td>2.1.2 Media</td>
<td>18</td>
</tr>
<tr>
<td>2.1.3 Kits</td>
<td>18</td>
</tr>
<tr>
<td>2.1.4 Equipment</td>
<td>18</td>
</tr>
<tr>
<td>2.1.5 Experimental Organism</td>
<td>18</td>
</tr>
<tr>
<td>2.1.6 Constructs</td>
<td>19</td>
</tr>
<tr>
<td>2.1.7 Morpholino oligonucleotides</td>
<td>24</td>
</tr>
<tr>
<td>2.2 Methods</td>
<td>24</td>
</tr>
</tbody>
</table>
2.2.1 *In vitro* synthesis of sense RNA for microinjection 24
2.2.2 *In vitro* synthesis of antisense RNA for *in situ* hybridization 24
2.2.3 *Xenopus* embryo microinjection 25
2.2.4 *Xenopus* explant assays and confocal microscopy 25
2.2.5 Whole mount *in situ* hybridization 27
2.2.6 RT-PCR 28
2.2.7 Cell culture and transfection 30
2.2.8 Antibody production and immuno-purification 30
2.2.9 Whole mount immuno-histochemistry with pH3 and dpERK 31
2.2.10 Immunoblotting 32
2.2.11 Dermatan sulfate preparation 32
2.2.12 Proteoglycan isolation and lyase treatment 32
2.2.13 Paraffin section 33
2.2.14 Hematoxylin eosin staining 33

3. **RESULTS**

3.1 Identification of *Xenopus* HtrA1 34
3.2 Expression of xHtrA1 35
3.3 Regulation of *xHtrA1* transcription by FGF signals 36
3.4 xHtrA1 blocks head formation and induces ectopic tails in a non-cell autonomous manner 38
3.5 Proteolytic activity is required for xHtrA1 effects 40
3.6 Effects of *xHtrA1* on embryonic patterning 42
3.7 xHtrA1 has posteriorizing effects on antero-posterior neural patterning 43
3.8 xHtrA1 dorsalizes the ectoderm and induces neuronal differentiation 45
3.9 xHtrA1 affects cell migration and promotes cell division 46
3.10 xHtrA1 is essential for proper axial development, mesoderm formation and neuronal differentiation 47
3.11 A neutralizing antibody against xHtrA1 anteriorizes embryonic development 50
3.12 HtrA1 cooperates with FGF signals 51
3.13 Role of FGF signals for the activity of xHtrA1 52
3.14 xHtrA1 activates FGF signaling 54
3.15 xHtrA1 stimulates FGF signaling at distance 55
3.16 xHtrA1 causes proteolytic degradation of Biglycan, Syndecan4, and Glypican4
3.17 Heparan sulfate and dermatan sulfate induce posteriorization, mesoderm and neuronal differentiation in an FGF-dependent manner

4. Discussion
4.1 Interaction with IGF and BMP antagonism are not sufficient to explain the activities of xHtrA1
4.2 xHtrA1 is a novel regulator of FGF signaling
4.3 A model for the regulation of FGF signals in the extracellular space
4.4 Specificity of xHtrA1-mediated regulation of FGF signaling
4.5 Implication of HtrA1 for mammalian development and disease

5. Conclusions
6. Bibliography
Curriculum Vitae

III
I would like to thank my supervisor Dr. Edgar M. Pera for his nice guidance throughout all of my master and Ph.D periods. I am very grateful to him for providing inspiring ideas, helpful discussions and suggestions, motivating my scientific interests, and giving strict academic training.

I express my gratitude to Professor Tomas Pieler for giving me the chance to start my master and then Ph.D in the department of developmental biochemistry at Georg August University Göttingen, Germany. I am grateful to Professor Tomas Pieler and Professor Michael Kessel for giving critical comments on my manuscript. I would also like to thank Professor Michael Kessel, Professor Ernst Wimmer, together with Professor Tomas Pieler, as my Ph.D committee members, for giving me valuable advises and supports during my Ph.D study.

I thank coordinators of the international MSc/Ph.D program in Molecular Biology, Max Planck Research School, Göttingen, Germany. Among them, I thank especially Dr. Steffen Burkhardt, for giving me great and continuous administrative supports during my whole study.

I would like to express my gratitude to many of my colleagues at the department of developmental biochemistry, Georg August University Göttingen, Germany. How can I ever forget our technician Ilona Wunderlich? She gave me great supports not only technically but also personally. I thank Dr. Yonglong Chen, Dr. Jacob Suoupgui, Fongcheng Pan, Ilona Wunderlich and Marion Dornwell for teaching me fundamental techniques in Xenopus field and giving technical advises. I enjoyed time with my good friends including Fongcheng Pan and Huiyuan Wu there.

I am very grateful to Sol Da Rocha Baez for helping us to solve lots of technical problems after moving to Lund Stem Cell Center, Sweden. Don’t forget to thank him also for giving us wonderful accompanies during coffee breaks, every Friday ‘Bara Ettan rock time’ and excursions, those nice memories I would always remember. I also couldn’t imagine my study could go so far without Dr. Marco Maccarana at the department of experimental and
medical science, Lund University, Sweden. Dr. Marco Maccarana, together with Professor Anders Malmström, gave us invaluable materials and reagents, which made it possible to systematically investigate the role of glycosaminoglycans in *Xenopus* early development. In addition, as our collaborator, Dr. Marco Maccarana greatly contributed to this study with his expertise in biochemistry analysis of proteoglycans.

I feel very lucky to work with my sweet colleagues Ina Strate and Shareen Tan, who are the kind of great colleagues everyone wishes to have. I am indebted to them for helping me so much, with all aspects, in finishing supplementary experiments within the last a few months. Apart from generating harmonious, joyful and efficient working atmosphere, they are also good and cute friends to have good time with after work.

I would also like to thank a lot of so-called ‘fly people’ and ‘eye people’ on the BMC B13: Wilma Martinez, Maria Thereza Perez, Shai Mulinari Schclarek, Birgitta Klefbohm, Kirsten Wunderlich, Julianne McCall, Stefan Baumgartner, Mojgan Padash, Dafne Lemus, Khalid Fahmy, Udo Häcker, Darren Cleare, Javier Sancho Pelluz, Jose Silva, Oliver Blechert, for their kind helps or encouragements.

Many thanks go to my parents and my elder brother for their love and support. I know that no matter where I am and what I do, they are always thinking of me and being there for me.
Abstract

Fibroblast growth factors (FGFs) are important signaling molecules, whose activities need to be tightly controlled. We have recently identified the *Xenopus* homolog of HtrA1 (xHtrA1) in a direct screen for secreted proteins (Pera et al., 2005). In this thesis, we show that xHtrA1 is co-expressed with FGF8 in the embryo, and that its expression is activated by FGF signals, suggesting that xHtrA1 belongs to the FGF8 synexpression group. Misexpression of xHtrA1 phenocopies multiple effects of FGFs, including posterior specification, mesoderm induction, neuronal differentiation, cell motility and proliferation. Downregulation of xHtrA1 activity via an antisense morpholino oligonucleotide or a polyclonal antibody leads to an overall phenotype reminiscent of FGF loss-of-function, with enlargement of head and reduction of ventroposterior structures. xHtrA1-MO also impairs mesoderm formation and neuronal differentiation. xHtrA1 cooperates with FGF and requires intact FGF signaling pathway for its patterning activities. xHtrA1 stimulates FGF/ERK activity, induces the transcription of FGF4 and FGF8 and allows long-range FGF signaling. In biochemical experiments, we could demonstrate that Biglycan, Syndecan4 and Glypican4 are cleaved by xHtrA1. In microinjected *Xenopus* embryos, purified heparan sulfate and dermatan sulfate induce posteriorization, mesoderm induction and neuronal differentiation in an FGF-dependent manner. These findings suggest that xHtrA1 may act as a positive feedback regulator of FGF signals that through proteolytic cleavage of proteoglycans allows long-range FGF signaling in the extracellular space.
# List of Figures

<table>
<thead>
<tr>
<th>Figures</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1. Protein structure of <em>Xenopus</em> HtrA1</td>
<td>34</td>
</tr>
<tr>
<td>Figure 2. Gene expression of <em>Xenopus</em> HtrA1</td>
<td>36</td>
</tr>
<tr>
<td>Figure 3. FGF is sufficient, but not required to induce xHtrA1</td>
<td>37</td>
</tr>
<tr>
<td>Figure 4. xHtrA1 induces ectopic tail-like structures in</td>
<td>39</td>
</tr>
<tr>
<td>a non-cell autonomous way</td>
<td></td>
</tr>
<tr>
<td>Figure 5. The proteolytic and the PDZ domain are required</td>
<td>41</td>
</tr>
<tr>
<td>for the activity of xHtrA1</td>
<td></td>
</tr>
<tr>
<td>Figure 6. xHtrA1 promotes posterior and mesoderm development</td>
<td>43</td>
</tr>
<tr>
<td>Figure 7. xHtrA1 posteriorizes the neural plate</td>
<td>44</td>
</tr>
<tr>
<td>Figure 8. Effects of xHtrA1 on ectodermal patterning</td>
<td>45</td>
</tr>
<tr>
<td>Figure 9. Effects of xHtrA1 on cell migration and proliferation</td>
<td>47</td>
</tr>
<tr>
<td>Figure 10. A morpholino oligonucleotide against xHtrA1 enhances anterior development and impairs mesoderm and neuronal differentiation</td>
<td>49</td>
</tr>
<tr>
<td>Figure 11. Blastuocoel injection of an anti-xHtrA1 antibody promotes anterior development</td>
<td>50</td>
</tr>
<tr>
<td>Figure 12. Effects of FGFs on embryonic development and cooperation with xHtrA1 during mesoderm induction</td>
<td>52</td>
</tr>
<tr>
<td>Figure 13. xHtrA1-mediated posteriorization, mesoderm induction and neuronal differentiation require intact FGF signaling</td>
<td>53</td>
</tr>
<tr>
<td>Figure 14. xHtrA1 activates ERK signaling and transcription of FGF8 and FGF4</td>
<td>55</td>
</tr>
<tr>
<td>Figure 15. xHtrA1 promotes long-range FGF signaling in the animal cap conjugate assay</td>
<td>56</td>
</tr>
<tr>
<td>Figure 16. xHtrA1 causes proteolytic cleavage of <em>Xenopus</em> Biglycan, Glypican4 and Syndecan4</td>
<td>59</td>
</tr>
<tr>
<td>Figure 17. Heparan sulfate and dermatan sulfate induce posteriorization, mesoderm and neuronal differentiation in an FGF-dependent manner</td>
<td>60</td>
</tr>
<tr>
<td>Figure 4.1 Model for the stimulation of long-range FGF signaling by the secreted serine protease xHtrA1.</td>
<td>69</td>
</tr>
</tbody>
</table>
### Abbreviation

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Adenine</td>
</tr>
<tr>
<td>AP</td>
<td>Alkaline phosphate buffer</td>
</tr>
<tr>
<td>ATP</td>
<td>adenosine triphosphate</td>
</tr>
<tr>
<td>BCIP</td>
<td>5-bromo-4-chloro-3-indolyl-Phosphate</td>
</tr>
<tr>
<td>BMB</td>
<td>Bohringer Mannheim Blocking Reagent</td>
</tr>
<tr>
<td>BMP</td>
<td>bone morphogenetic protein</td>
</tr>
<tr>
<td>bp</td>
<td>base pairs</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>C</td>
<td>cytosine</td>
</tr>
<tr>
<td>°C</td>
<td>celsius degree</td>
</tr>
<tr>
<td>cDNA</td>
<td>complementary DNA</td>
</tr>
<tr>
<td>CHAPS</td>
<td>3-(3-cholamidopropyl)dimethylammonio-1-Propansulphate</td>
</tr>
<tr>
<td>CFP</td>
<td>canyon fluorescent protein</td>
</tr>
<tr>
<td>ddH2O</td>
<td>Distilled water</td>
</tr>
<tr>
<td>DIG</td>
<td>Digoxigenin-11-2′-deoxyuridin-5′-triphosphate</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethylsulfoxide</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>DNase</td>
<td>Deoxyribonuclease</td>
</tr>
<tr>
<td>DTT</td>
<td>dithiothreitol</td>
</tr>
<tr>
<td>E.coli</td>
<td>Escherichia coli</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylenediaminetetraacetic acid</td>
</tr>
<tr>
<td>et al.</td>
<td>et alii</td>
</tr>
<tr>
<td>HEPES</td>
<td>4-(2- Hydroxyethyl)-1-piperazin</td>
</tr>
<tr>
<td>G</td>
<td>guanine</td>
</tr>
<tr>
<td>GPI</td>
<td>glycosylphosphatidylinositol</td>
</tr>
<tr>
<td>h</td>
<td>hours</td>
</tr>
<tr>
<td>HCG</td>
<td>human chorionic gonadotropin</td>
</tr>
<tr>
<td>kb</td>
<td>kilobase</td>
</tr>
<tr>
<td>L</td>
<td>liter</td>
</tr>
<tr>
<td>LB</td>
<td>Luria-Bertani (medium)</td>
</tr>
<tr>
<td>m</td>
<td>milli</td>
</tr>
<tr>
<td>µ</td>
<td>micro</td>
</tr>
<tr>
<td>M</td>
<td>molar (mol/l)</td>
</tr>
<tr>
<td>MAB</td>
<td>malic acid buffer</td>
</tr>
<tr>
<td>MEM</td>
<td>MOPS-DGTA-MgSO4-Buffer</td>
</tr>
<tr>
<td>MEMFA</td>
<td>MOPS-DGTA-MgSO4-Formaldehyde-Buffer</td>
</tr>
<tr>
<td>min</td>
<td>minutes</td>
</tr>
<tr>
<td>MOPS</td>
<td>4-Morpholinpropanosulfonic acid</td>
</tr>
<tr>
<td>mRNA</td>
<td>messenger RNA</td>
</tr>
<tr>
<td>NaAc</td>
<td>sodium acetate</td>
</tr>
<tr>
<td>OD</td>
<td>optical density</td>
</tr>
<tr>
<td>PAGE</td>
<td>polyacrylamide gel electrophoresis</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PBSw</td>
<td>1% Tween-20 in PBS</td>
</tr>
<tr>
<td>PDZ</td>
<td>PSD95/DlgA/ZO-1 homology</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>pH</td>
<td>preponderance of hydrogen ions</td>
</tr>
<tr>
<td>%</td>
<td>percent</td>
</tr>
<tr>
<td>Red-gal</td>
<td>5-Bromo-6-Chloro-3-indolyl-1-Dgalactopyranoside</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>reverse transcriptase-PCR</td>
</tr>
<tr>
<td>sec</td>
<td>second</td>
</tr>
<tr>
<td>SSC</td>
<td>standard saline citrate buffer</td>
</tr>
<tr>
<td>T</td>
<td>Thymine</td>
</tr>
<tr>
<td>Taq</td>
<td><em>Thermus aquaticus</em></td>
</tr>
<tr>
<td>TAE</td>
<td>Tris-Acetic acid-EDTA-Electrophoresis buffer</td>
</tr>
<tr>
<td>Tm</td>
<td>melting temperature</td>
</tr>
<tr>
<td>U</td>
<td>units</td>
</tr>
<tr>
<td>UV</td>
<td>ultra violet light</td>
</tr>
<tr>
<td>Vol.</td>
<td>volume</td>
</tr>
<tr>
<td>X-Gal</td>
<td>5-Bromo-4-Chloro-3-indolyl-1-Dgalactopyranoside</td>
</tr>
<tr>
<td><em>X. laevis</em></td>
<td><em>Xenopus laevis</em></td>
</tr>
</tbody>
</table>
1 Introduction

1.1 Xenopus laevis as model system for developmental biology

The establishment of the vertebrate body plan is a topic of considerable interest in developmental biology. The amphibian embryo has been a fruitful experimental system for these investigations because of its large egg size, its external embryonic development, and its ability to easily heal after microsurgery. These features are important prerequisites for studying the early development of the embryonic axis. Classical experimental approaches, such as fate mapping, transplantation experiments and explant cultures, together with molecular biology methods make the Xenopus embryo an excellent model to unravel the signaling network underlying body axis patterning. Overexpression of genes can be quickly and easily done by microinjection of in vitro synthesized RNA, DNA or proteins. Downregulation of gene activity can be achieved by injecting antisense morpholino oligonucleotides or, in the case of extracellularly expressed proteins, by injecting antibodies into the blastocoel cavity. In order to block a certain molecular pathway, dominant negative receptors, dominant negative signaling intermediates or pharmacological inhibitors can be injected. Animal cap explants resemble mammalian embryonic stem cells with respect to their pluripotency to give rise to derivatives of all three germ layers in vitro, when exposed to appropriate signaling factors, and provide a strong tool to study the molecular basis of embryonic induction and cell lineage specification.

1.2 The breakage of symmetry in Xenopus embryos

In Xenopus, the first body axis to be established is the dorsoventral (DV) axis. Upon entry of the sperm into the animal hemisphere, the outer layer of the egg rotates relative to the yolk core cytoplasm. This cortical rotation and the assembly of subcortical microtubule (MT) bundles translocate dorsal determinants from the vegetal part to the future dorsal side, which is opposite to the sperm entry site (Elinson and Rowning, 1988, review see Weaver et al., 2004). The dorsal determinants consist of Dishevelled (Dsh) and Glycogen Synthase Kinase 3 (GSK3)-binding protein (GBP). Microinjection of Dsh or GBP mRNA into early Xenopus embryos leads to the formation of a complete dorsal axis (Yost et al., 1998; Sokol et al., 1995). Conversely, when GBP is depleted by injecting antisense oligonucleotides into Xenopus oocyte, the dorsal axis fails to form (Yost et al., 1998). The dorsal determinants are transported to the future dorsal side via the track of microtubules
through interaction of GBP and kinesin light chain (KLC), which forms a heterotetrameric microtubule motor of kinesin. Both GBP and Dsh are involved in activation of the canonical Wnt pathway. GBP binds directly to Dsh, a GSK3 inhibitor that is activated by a canonical Wnt pathway (Yost et al., 1998; Li et al., 1999; Salic et al., 2000). In addition, GBP binds to GSK3 and causes the degradation of GSK3 (Domínguez and Green, 2000; Farr et al., 2000). The dorsal-localized GBP and Dsh prevent GSK3 from phosphorylating β-catenin. As a result, β-catenin is prevented from being degraded in the ubiquitin-proteasome pathway and accumulates in the nuclei on the dorsal side of the embryo. As a transcription factor, β-catenin binds to the transcriptional repressor complex containing T-cell factor/Lymphoid enhancer factor (TCF/LEF) transcription factors, converts the complex into an activator, and initiates the transcription of Wnt target genes (for review see Miller et al., 1999). The intracellular components of the Wnt pathway are clearly involved in Xenopus axis specification. Recently, the extracellular signal Wnt11, which is maternally enriched on the dorsal side of two-cell stage embryos (Shroeder et al., 1999), has been demonstrated to be crucial for axis formation in Xenopus embryos (Tao et al., 2005).

1.3 Mesoderm induction during embryogenesis

During early Xenopus development, the mesoderm forms in the equatorial region of the blastula embryo. Classical recombination experiments have shown that mesoderm tissue is induced in the animal cap ectoderm juxtaposed to vegetal endoderm explants (Nieuwkoop 1969; Gilbert 2003), indicating that the animal hemisphere responds to signals emitted from the underlying vegetal pole and adopts a mesoderm fate in the marginal zone. The induced mesoderm then differentiates into prechordal plate, notochord, somite, kidney, lateral plate mesoderm and ventral blood islands in a dorsal to ventral order (De Robertis and Kuroda, 2004). A variety of proteins and transcription factors have been tested for the mesoderm-inducing activity in the animal cap assays.

Members of the TGF-β superfamily have been shown to have the capability to induce mesoderm. A Xenopus homologue of activin A can induce animal cap explants to form several different types of mesoderm in a dose dependent manner, with low doses of activin A generating ventral mesoderm, such as mesenchyme and blood island cells, and higher doses inducing more dorsal mesoderm, such as segmented muscles, pronephros and
notochord (Smith et al., 1990; Green et al., 1990). A *Xenopus* homologue of activin B has a similar mesoderm-inducing activity like activin A (Thomsen et al., 1990), whereas, activin D is a less potent mesoderm inducer (Oda et al., 1995). The protein of activin A and B and the transcripts of activin D are found maternally before midblastula transition (Fukui et al., 1994; Dohrmann et al., 1993; Rebagliati and Dawid, 1993, Fukui et al., 1999; Oda et al., 1995), at the time when mesoderm induction takes place. However, mRNAs and proteins of all activin isoforms are ubiquitously distributed throughout the three germ layers, which cannot explain the formation of the mesoderm only in the marginal zone, suggesting that other vegetal-localized signals may be involved in the induction of mesoderm. Vg1 is a member of the TGF-β family, both mRNA and protein are maternally expressed and localized in the prospective endoderm (Weeks and Melton, 1987). Experiments with a chimeric Vg1, which can be efficiently processed *in vivo*, demonstrate that Vg1 has potent dorsal mesoderm-inducing abilities in the animal cap explants (Thomsen and Melton, 1993; Dale et al., 1993). Treating animal caps with mature Vg1 protein leads to the upregulation of *Xenopus* nodal related 1 (Xnr1), which is another mesoderm-inducing factor (Agius et al., 2000). However, the mature processed Vg1 protein is not endogenously detected before gastrulation (Tannahill and Melton, 1989).

Recently, Birsoy and colleagues showed that Vg1-depleted *Xenopus* embryos exhibit lack of dorsal mesoderm structures and this effect can be partially rescued by a second allele of Vg1, which can be processed successfully *in vivo*. Overexpression of this efficiently processed Vg1 induces mesoderm marker expression in animal cap explants (Birsoy et al., 2005). Several BMPs, including BMP2, BMP4, BMP7, are abundant as maternal mRNAs in the animal hemisphere (Koster et al., 1991; Nishimatsu et al., 1992; Dale et al., 1992; Jones et al., 1992). Overexpression of BMPs in naive animal cap explants causes the formation of ventral mesoderm derivatives including mesenchyme, blood islands and muscle but not dorsal mesoderm-like notochord (Dale et al., 1992; Jones et al., 1992; Garff et al., 1994; Suzuki et al., 1994; Hemmati-Brivanlou and Thomsen, 1995). VegT is a T-box transcription factor, whose mRNA is maternally transcribed and restricted to the vegetal hemisphere of eggs and embryos (Stennard et al., 1996; Lustig et al., 1996; Zhang and King, 1996). The temporal and spatial expression pattern suggest that VegT may be one of the endogenous mesoderm-inducing signals secreted from the vegetal pole. Indeed, microinjection of synthetic *VegT* mRNA can specify mesodermal fates in animal caps (Stennard et al., 1996; Lustig et al., 1996; Zhang and King, 1996). Eliminating maternal
VegT transcripts in oocytes by antisense oligonucleotides blocks the mesoderm-inducing activity of vegetal pole explants in Nieuwkoop ectoderm-endoderm combination experiment and disrupts formation of mesoderm tissues in whole embryos (Kofron et al., 1999). These experiments suggest that VegT may act as an endogenous factor to initiate mesoderm formation in the overlying equatorial plane.

The evidence that disruption of TGF-β signaling by the dominant negative activin receptor tAR (Hemmati-Brivanlou and Melton, 1992) blocks VegT-mediated mesoderm induction, showed that the mesoderm inducing activity of VegT depends on an intact TGF-β pathway (Clements et al., 1999). After the mid-blastula transition, the maternally expressed VegT protein on the vegetal pole activates transcription of the Xenopus nodal-related genes Xnr 1,2,4,5,6, that all have the ability to induce mesoderm formation in animal cap explants (Hyde and Old, 2000; Clements et al., 1999; Kofron et al., 1999; Xanthos et al., 2001). On the dorsal side of the embryo, nuclear-localized β-catenin upregulates Xnr (Agius et al., 2000; Takahashi et al., 2000). Within the endoderm, the dorsal-localized β-catenin cooperates with the vegetal VegT to generate an Xnr gradient with lower Xnr activity on the ventral side and higher activity on the dorsal side. High levels of nodals induce dorsal mesoderm in the overlying equatorial zone, whereas low levels of nodal signal induce more ventral mesoderm (Agius et al., 2000). Another VegT target gene is Derrière, a vegetally expressed TGF-β family member, whose zygotic transcription is initiated by maternal VegT. Derrière was shown to be potent for mesoderm and endoderm induction. A dominant negative Derrière construct (Cm-Derrière) ablates posterior- and paraxial- mesoderm specific gene expression, suggesting that Derrière is crucial for mesoderm patterning. (Sun et al., 1999) In sum, the maternally expressed signals from the vegetal pole, such as VegT and likely also Vg1, activate the gene expression of members of the TGF-β family including Xnrs and Derrière in the endoderm after mid-blastula transition, these members together with ubiquitously expressed activin contribute to the initiation of mesoderm formation on the cells overlying endoderm.

1.4 The formation of the Spemann-Mangold organizer
Hans Spemann and Hilde Mangold reported that the dorsal blastopore lip of an amphibian gastrula embryo has the ability to induce a twin body axis, when transplanted into the ventral side of a sibling host embryo (Spemann and Mangold, 1924). Specifically, the
organizer tissue induces a central nervous system (CNS) in the ectoderm, dorsalizes the mesoderm and endoderm, and induces gastrulation movements. The dorsal accumulation of β-catenin activates the expression of Wnt target genes, such as the homeobox gene Siamois. Siamois synergizes with the vegetal-localized TGF-β family members Vg1 and Nodal-related proteins to activate the Goosecoid gene (Laurent et al., 1997; Brannon and Kimelman, 1996; Agius et al., 2000). Goosecoid is another homeobox-containing transcription factor that activates various target genes that encode antagonists against BMP, Wnt and the Nodal pathway. The group of cells in the dorsal mesoderm that receive both β-catenin signal from the dorsal side and Vg1, VegT and Nodal-related proteins from the vegetal side give rise to the Spemann-Mangold organizer.

1.5 The default model of neural induction

The CNS is derived from the dorsal ectoderm or neuroectoderm, whereas the ventral ectoderm gives rise to epidermis. The Spemann-Mangold organizer transplantation experiment showed that the dorsal blastopore lip can convert epidermis into neural tissues. Dissociated animal cap cells from Xenopus laevis adopt a neural fate, suggesting that a neural character could derive from ectoderm in the absence of the Spemann-Mangold organizer or other exogeneous signals (Godsave et al., 1988; Grunz and Tacke, 1990; Sato and Sargent 1989). This together with the observation that a dominant negative activin receptor (ActRIIB), which blocks the BMP pathway (Dale and Jones, 1999), induced neural tissue in animal cap explants (Hemmati-Brivanlou and Melton, 1992), leads to the idea of the default model of neural induction. This model suggests that the ectoderm by default gives rise to neural tissue rather than epidermis tissue in the absence of epidermis-inducing factors (Gilbert, 2003).

Several experiments from Xenopus research groups support the default model. Members of the TGF-β superfamily, such as BMP2, BMP4, BMP7 and growth and differentiation factor 6 (GDF6) were shown to repress neural-specific and induce epidermal markers in dissociated animal caps (Suzuki et al 1997; Wilson and Hemmati-Brivanlou 1995; Chang and Hemmati-Brivanlou, 1999). These factors are initially expressed ubiquitously in the ectoderm, but as gastrulation proceeds, they are excluded from the prospective neural plate (Hemmati-Brivanlou and Thomsen 1995; Hawley et al., 1995; Chang and Hemmati-Brivanlou, 1999). Activation of BMP signaling stimulates epidermal and represses neural
tissue development. Constitutively active BMP receptors, such as Alk2, Alk3, and Alk6, or of the BMP intermediates Smad1 and Smad5, induce epidermis marker in dissociated animal cap explants (Suzuki et al. 1997a, b; Wilson et al. 1997). In contrast, inhibition of the BMP pathway is sufficient to promote neural fate in ectodermal explants or whole embryos. Simultaneous depletion of endogenous BMP2, BMP4 and BMP7 by injecting antisense morpholino oligonucleotides led to embryos with significantly enlarged neural plates (Reversade et al., 2005). Quadruple knockdown of BMP2, BMP4, BMP7 and the organizer-specific TGF-β factor ADMP (anti dorsalizing morphogenetic protein) caused completely neuralized embryos devoid of any epidermis (Reversade and De Robertis, 2005). Soluble antagonists of bone morphogenetic proteins (BMPs), including noggin (Lamb et al., 1993), chordin (Sasai et al., 1995), follistatin (Hemmati-Brivanlou et al., 1994) and Xnr3 (Hansen et al., 1997) are secreted from the Spemann-Mangold organizer near the prospective neural plate. Microinjection of each of these mRNAs is able to induce anterior neural markers in animal cap explants. Connective-tissue growth factor (CTGF), which expressed in CNS derivatives, such as the floor plate, blocks BMP transduction by sequestering the ligand and preventing it from interacting with BMP receptors. Injection of CTGF RNA into animal cap explants induced neural marker expression (Abreu et al., 2002). Overexpression of two inhibitory Smads, Smad6 (Hata et al., 1998) and Smad7 (Souchelnytskyi et al., 1998; Casellas and Brivanlou, 1998) or injection of ectodermin, a Smad4 ubiquitin ligase involved in the degradation of Smad4 (Dupont et al., 2005), blocks BMP transduction and leads to neural tissue induction. Overexpression of Smurf1 (Zhu et al., 1999), Smurf2 (Zhang et al., 2001), which are E3 ubiquitin ligases that degrade Smad effectors in the BMP pathway, or Smad interacting protein 1 (SIP1) (Nitta et al., 2004) all antagonize BMP signaling and give rise to neural induction in animal cap tissues. The secreted protein Cerberus, which is a triple inhibitor of BMP, Wnt8 and Nodal signals, is expressed in the anterior endoderm, in close vicinity to the presumptive forebrain tissue. Microinjection of Cerberus mRNA led to ectopic head structure and neural tissue formation in whole embryos (Bouwmeester et al., 1996). Coco, expressed in the ectoderm until the end of gastrulation, is a maternal Cerberus/Dan like inhibitor of BMP, TGF-β and Wnt signaling. Overexpression of Coco caused neural marker induction in animal caps (Bell et al., 2003). In sum, research in Xenopus favors the idea that ubiquitously expressed BMPs prevent ectoderm cells from adopting their default neural fate. The inhibition of BMP signaling in the dorsal ectoderm by BMP antagonists from the ectoderm, underlying
dorsal mesoderm (Spemann-Mangold organizer) or anterior endoderm permit ectoderm cells to execute their natural tendency to generate neural tissue (for review see Vonica and Hemmati-Brivanlou, 2006).

Recent research suggests that neural induction takes place as early as the blastula stage, before the Spemann-Mangold organizer forms. At mid-blastula, the ectoderm starts to express distinct markers along the dorsal-ventral axis, suggesting that ectodermal cells are already specified (Gamse and Sive, 2001; Kroll et al., 1998). In the blastula stage, the nuclear translocation of β-catenin in the dorsal ectoderm induces the expression of BMP antagonists such as Chordin and Noggin (Wessely et al., 2001). Consequently, this dorsal ectoderm area was designated as BCNE center (Blastula Chordin and Noggin Expression center, Kuroda et al., 2004). The BCNE center has been shown to be required for neural specification, since brain formation was impaired when the BCNE center was excised. Moreover, the BCNE still formed neural tissue in embryos injected with the Nodal inhibitor Cerberus-short, indicating that the CNS develops in the absence of mesoderm. This experiment suggests that neural specification is initiated before establishment of the Spemann-Mangold organizer.

In agreement with the default model of neural induction by antagonizing BMP signaling, several pieces of evidence showed that enhancement of BMP signaling activates a number of transcription factors including Msx1, Gata1 and Vent1 and Vent2 proteins (Suzuki et al., 1997c; Xu et al., 1997; Onichtchouk et al., 1996), which act as transcriptional repressors and inhibit expression of the neural inducer SoxD (Mizuseki et al., 1998; Sasai, 1998). Conversely, blockage of BMP signal transduction relieves the repression of SoxD by downregulation of BMP target genes. Expression of SoxD leads to the induction of Ngnr1 and the onset of neuronal development (Mizuseki et al., 1998).

1.6 Other signals involved in neuralization

Studies in amphibian and amniotes suggest that the competence, specification, commitment and differentiation of neural character from naive ectoderm may not simply result from inhibiting the BMP pathway, but instead require the integration of multiple signals. Wnt signaling has been implicated in the selection of neural or epidermal fate. The acquisition of neural fate can be regarded as the dorsalization of ectoderm, which results
from dorsal-ventral axis formation soon after fertilization. The future dorsal side is determined by the nuclear accumulation of the Wnt effector β-catenin. Therefore, activation of Wnt signaling by injecting mRNAs encoding Wnt or its signal mediators into the animal hemisphere of very early embryos generates a dorsalized phenotype with ectopic neural tissues. Activation of early Wnt signaling induced neural marker gene expression in animal caps as well (Baker et al., 1999). Although early Wnt signaling is sufficient for ectopic neural induction, in later development, Wnt signaling eventually suppresses the generation of neural cells (for review see Logan and Nusse, 2004). Expression of several Wnt inhibitors induces neural markers in the animal cap assay (Glinka et al., 1997, 1998). Studies in chick indicated that in the lateral epiblast cells, where Fibroblast growth factors and Wnt exist, Wnt blocks the response of epiblast cells to FGFs, which allows BMP transcription to occur and epidermis to form. Inhibition of the Wnt pathway is sufficient and necessary to elicit epidermal lateral epiblast cells to adopt neural fate (Wilson et al., 2001).

Insulin growth factor (IGF) was shown to be both sufficient and required for the induction of ectopic head structures in whole embryos. In animal cap explants, IGF1 and IGF2 mRNA had the ability to induce anterior neural tissues without mesoderm formation and the neural induction by Chordin was inhibited when IGF signals were attenuated. (Pera et al., 2001; Richard-Parpaillon et al., 2002). The evidence that activation of IGF counteracted Wnt8, dominant negative GSK3 and β-catenin, but not the activated form of Tcf, suggest that IGF signals inhibit Wnt signaling downstream of β-catenin (Richard-Parpaillon et al., 2002). Activation of IGF1R by IGF1 or IGF2 can activate the Ras-MAP kinase pathway or the PI3 kinase (phosphatidylinositol-3 kinase)-Akt pathway (Blume-Jensen Hunter et al., 2001). Both an active PI3K subunit and Akt can, induce secondary axes in mRNA-injected Xenopus embryos and neuralization in injected animal caps. This ability was mediated by inhibiting GSK3β and therefore antagonizing the Wnt pathway (Peng et al., 2004).
translocating into the nucleus, and hence inhibits Smad activity (Kretzschmar et al., 1997; Massague, 2003). This effect counteracts the one of C-terminal Smad phosphorylation by the BMP receptor serine-threonine protein kinase and allows neural induction to occur (Pera et al., 2003). Recently, it was shown that the auto-neuralization observed in dissociated animal caps requires sustained MAPK activity, since blocking the MAPK pathway at different intracellular levels eliminated the neural marker induction and maintained the epidermal marker expression instead (Kuroda et al., 2005). The neuralization in this system also relied on the inhibition of BMP/Smad1 activity through MAPK. In sum, neural induction requires low levels of Smad1 activity, achieved by attenuating C-terminal phosphorylation mediated by BMP pathways, and elevating linker phosphorylation by FGF or IGF through MAPK (Kuroda et al., 2005).

1.7 Regional specification of the central nervous system

Nieuwkoop suggested a two-step model for the induction and regional specification of the central nervous system (Gilbert, 2003). During the first step („activation“), signals from the early invaginating endomesoderm induce neural tissue of an anterior or forebrain-like type. During the second step („transformation“), signals from later invaginating mesoderm cells convert this anterior neural tissue gradually into more posterior neural tissue, giving rise to midbrain, hindbrain and spinal cord. Studies in Xenopus have shown that the activation step is mediated by soluble antagonists of bone morphogenetic protein (BMP) and Wnt signals (De Robertis and Kuroda, 2004; Niehrs, 2004). Chordin, Noggin and Follistatin directly bind to and inhibit BMP ligands in the extracellular space. Frzb-1 and Dickkopf-1 specifically block Wnt signaling. The head inducer Cerberus acts as a triple inhibitor of BMP, Wnt and Nodal signals. In addition, IGFs contribute to head and neural induction through antagonizing BMP and Wnt signaling at an intracellular level (Pera et al., 2001, 2003; Richard-Parpaillon et al., 2002). The transforming step is mediated by retinoic acid, Wnt and FGF signals (Maden, 2002; Niehrs, 2004; Böttcher and Niehrs, 2005).

1.8 Fibroblast growth factor signaling

Fibroblast growth factors (FGFs) comprise a family of at least 22 secreted proteins. They signal through FGF receptors, encoded by four distinct genes \textit{FGFR1-4} and several splicing isoforms that together form a subfamily of cell surface receptor tyrosine kinases
(RTKs). Binding of FGF ligands causes receptor dimerisation and tyrosine kinase activation, leading to the activation of phospholipase C-γ (PLC-γ), phosphatidylinositol-3-kinase (PI3K), and the Ras to extracellular signal regulated protein kinase (ERK) pathways. ERKs are a subclass of the mitogen activated protein kinases (MAPKs).

These pathways regulate a number of biological phenomena, including cell proliferation, differentiation and migration. During early vertebrate development, FGF signaling is crucial for the induction of mesoderm and endoderm, neural fate specification, axial polarity and morphogenetic movements (Böttcher and Niehrs, 2005). Studies in *Xenopus* have first demonstrated a role of FGFs in the induction and migration of mesoderm during trunk and tail development (Slack et al., 1996). In chick and *Xenopus* embryos, FGFs participate in the induction of neural fate (Hongo et al., 1999; Streit et al., 2000; Wilson et al., 2000; Hardcastle et al., 2000; Pera et al., 2003; De Robertis and Kuroda, 2004). In addition, FGFs act as posteriorizing factors during anteroposterior patterning of the central nervous system (Lamb and Harland, 1995; Cox and Hemmati-Brivanlou, 1995). Then, FGFs are involved in many later cell interactions, patterning the telencephalon and midbrain-hindbrain boundary (Dono, 2003), during limb outgrowth (Martin, 1998), bone formation (Ornitz, 2005), angiogenesis (Presta et al., 2005) and in cancer (Grose and Dickson, 2005).

### 1.9 FGFs in mesoderm induction

Members of FGF family are present in blastula stage embryos, suggesting an involvement in mesoderm formation (Slack et al., 1987; Kimelman et al., 1988; Isaacs et al., 1992). Purified bovine bFGF can convert animal cap explants into ventral mesoderm tissues, such as mesenchyme, mesothelium and blood cells (Kimelman and Kirschner, 1987). However, since bFGF lacks a signal sequence, it remains unclear how this protein could participate in signal transduction events (Kimelman et al., 1988). *Xenopus* embryonic FGF (XeFGF), a homologue of human FGF4, has a detectable signal peptide and can be efficiently secreted. The expression of FGF4 is maternal and increases significantly when gastrulation starts. During gastrulation, FGF4 transcripts are restricted to the mesoderm around the blastopore ring (Isaacs et al., 1992). It has been found that FGF4 has robust mesoderm-inducing activity in mRNA-injected animal caps (Isaacs et al., 1994). FGF4 has been shown to generate a positive autoregulatory loop with the T-box transcription
factor Xbra, in which each factor activates the transcription of the other, hence stabilizing mesoderm formation in the marginal zone (Isaacs et al., 1994). Exogenously added bFGF, FGF4 or activated Ras induces ectopic expression of mesodermal marker genes in vegetal explants where the activin-like signal exists (Cornell et al., 1995). This experiment suggests FGF act as a competence factor in the marginal zone, allowing marginal zone cells to respond to the activin-like signal and form mesoderm.

Several pieces of evidence support that FGF signals are essential for mesoderm induction. Inhibition of FGF signaling by a dominant inhibitory FGFR1 construct (XFD) results in the blockage of mesoderm, including notochord, muscle and ventral mesoderm, and prevents posterior cells from undergoing proper gastrulation movements (Amaya et al, 1991, 1993). XFD, or two dominant negative effectors of the MAPK pathway, c-Ras and c-Raf, inhibit the ability of activin to induce both dorsal and ventral mesoderm markers, suggesting the requirement of FGF signals for mesoderm induction by activin. Therefore FGF signaling appears to be a permissive signal to permit activin-mediated mesoderm induction (LaBonne and Whitman 1994; Cornell et al., 1995). In mice, FGF4 and FGF8 are required for the migration of cells out of the primitive streak and thus for the formation of mesoderm (Sun et al., 1999). FGF signals are also essential for the migration and patterning of mesoderm in Drosophila (Huang and Stern, 2005).

1.10 FGFs in neural induction

A role of FGFs has been suggested during neural induction. Basic FGF can induce gastrula stage ectoderm cells to express neural markers along the anterior-posterior axis in a dose-dependent manner, with lower doses inducing anterior neural marker genes and higher doses more posterior neural markers. This neural inducing activity is direct, since the applied dose of basic FGF was 50 fold lower than that required to induce mesoderm, and did not induce transcription factors expressed in the Spemann-Mangold organizer (Kengaku and Okamoto, 1993, 1995). Basic FGF induced pan-neural marker gene expression in early to late gastrula ectoderm without mesoderm formation. Moreover, the anterior-posterior neural character induced by bFGF also depended on the age of gastrula ectoderm, with early gastrula ectoderm expressing posterior neural markers and older ectoderm being competent to form more anterior neural markers (Lamb and Harland 1995). A constitutively active chimeric FGFR1 induced the upregulation of posterior
neural markers such as Krox20 and HoxB9 in animal caps neuralized by dominant negative type II activin/BMP4 receptor (ActRIIB). When a constitutively active FGFR4 was injected into ectoderm that had been neuralized by ActRIIB, more anterior midbrain markers such as En2 and Wnt1 were induced. This inducing activity required the PLC-γ pathway, since a FGFR4 mutant, in which a conserved tyrosine residue was mutated and cannot bind to PLC-γ, completely blocked induction of these midbrain markers (Umbhauer et al., 2000). FGF8 mRNA injection was shown to induce ectopic neural markers in whole embryos (Hardcastle et al., 2000).

Intact FGF signaling is required for neural induction. Overexpression of a dominant negative FGFR4a construct (DnFGFR4a), which lacks the intracellular tyrosine kinase domain, led to the loss of telencephalon and eye structures. Furthermore, the DnFGFR4a inhibited neural marker gene expression induced by the Spemann-Mangold organizer or prolonged dissociation of ectodermal explants (Hugo et al., 1999). Similarly, neural induction and neural differentiation was diminished by DnFGFR4a, as judged by the loss of the early pan-neural marker Sox2 and the neuronal marker N-tubulin (Hardcastle et al., 2000; Delaune et al., 2005). Overexpression of another dominant negative FGFR1 (XFD) blocked neural induction in animal cap explants that had been injected with Noggin or Chrodin (Launay et al., 1996; Sasai et al., 1996), or recombined with Spemann-Mangold organizer (Launay et al., 1996). The FGFR1 inhibitor SU5402 induced defects including impairment of neural tissues and loss of axial tissue from posterior to anterior in a dose-dependent manner. SU5402 prevented neural induction of ectodermal explants by the Spemann-Mangold organizer, or by Noggin, dominant negative BMP receptor (tBR) and Smad6 mRNA injection (Delaune et al., 2005). Similarly, in chick embryos, FGF signaling is also required for neural induction. At the blastula stage, FGF3 is expressed in the neurogenic medial ectoderm. When a medial ectoderm explant was treated with the FGFR1 antagonists SU5402, BMP transcription was upregulated and the tissue acquired an epidermal fate, suggesting that endogenous FGF signals may attenuate BMP signals (Wilson et al., 2000). The observation that addition of BMP antagonists can restore neural fate of medial epiblast explants that have been treated with low but not with high doses of the FGFR antagonist suggested that apart from merely inhibiting BMP transcription, FGFs activate an independent pathway to promote neural fate (Wilson et al., 2000, 2001).
1.11 FGFs in posterior development

Apart from its ability to initiate a neural character, FGFs have also been shown to caudalize neural tissues (for review see Doniach, 1995). In *Xenopus*, the cement gland is the rostral-most structure at the anterior ridge of the neural plate (Sive and Bradley, 1996), which responded to very low BMP activity and was detected in dissociated animal cap explants. Addition of bFGF protein transformed dissociated ectoderm explants into more posterior structures (Lamb and Harland, 1995). Similarly, the transcription factor Sox2 can induce cement gland differentiation in ectoderm explants, and supplemented bFGF induced neural tissue (Mizuseki et al., 1998a). Anterior neural tissues induced in animal caps by BMP antagonists such as Noggin, Follistatin or Chordin were converted to form posterior neural tissues in the presence of bFGF proteins (Lamb and Harland, 1995; Cox and Hemmati-Brivanlou, 1995; Sasai et al., 1996). Applying bFGF protein to presumptive hindbrain tissues induced spinal cord marker gene expression (Cox and Hemmati-Brivanlou, 1995). In whole embryos, FGF8 induced a transformation of the caudal diencephalon to more posterior midbrain structures. When FGF4- or FGF8-soaked beads were implanted into the prospective forebrain regions of neurula or tailbud stage *Xenopus* embryos, ectopic expression of the midbrain markers En2 and Wnt1 was observed (Riou et al., 1998). A similar posteriorizing effect of FGF8 was observed in chick embryos (Crossley et al., 1996). In addition, FGF8 mutants in mouse and zebrafish lack posterior midbrain and cerebellar tissues (Meyers et al., 1998; Reifers et al., 1998), pointing towards a pivotal role of FGF8 in the development of the midbrain in vertebrate embryos.

1.12 Proteoglycans as regulators of FGF signaling

Proteoglycans are abundant extracellular molecules that consist of a protein core to which highly sulfated glycosaminoglycan (GAG) residues are covalently attached. According to their sugar composition, the GAG chains are classified as heparan sulfate, chondroitin sulfate or dermatan sulfate (Iozzo, 1998; Bernfield et al., 1999; Buelow and Hobert, 2006). Glypicans and Syndecans are two major cell surface heparan sulfate proteoglycans. Members of the small leucine-rich proteoglycan family, such as Decorin and Biglycan, are associated with the cell surface or pericellular matrix, and belong to the chondroitin or dermatan sulfate proteoglycans. Biochemical and cell culture experiments have identified proteoglycans as co-regulators of several growth factors, among them FGFs. Binding of FGFs to heparin or heparan sulfate is crucial for efficient receptor stimulation (Lin et al.,
Similarly, dermatan sulfate binds to FGFs and potentiates their activity (Penc et al., 1998; Trowbridge et al., 2002; Taylor et al., 2005). In genetic analyses, mutations in the enzymes responsible for the biosynthesis of GAG chains have demonstrated the importance of proteoglycans for FGF signalling during development (Lin, 2004; Buelow and Hobert, 2006). For example, mice mutated in UDP-glucose dehydrogenase (Ugdh), an enzyme required for GAG biosynthesis, arrest during gastrulation and display defects in mesoderm and endoderm migration reminiscent of mutants in the FGF pathway (Garcia-Garcia and Anderson, 2003). In the Ugdh mutant embryos, FGF signaling is specifically blocked. In Drosophila, Ugdh mutants also exhibit phenotypes similar to FGFR mutants (Lin et al., 1999), suggesting an evolutionarily conserved function for HSPGs (Heparan sulfate proteoglycans) in FGF signaling.

1.13 HtrA superfamily
HtrA1 belongs to the HtrA (High temperature requirement) family of serine proteases that is well conserved from bacteria to humans (for review, see Clausen et al., 2002). The defining structural feature is the combination of a catalytic domain resembling trypsin with one or more C-terminal peptide binding (PDZ) domains. The founding member of the family has been identified as a heat shock protein in Escherichia coli (HtrA, DegP) and is a key factor in the control of protein stability and turnover. In mammals, four homologs have been reported (HtrA1-4). Mitochondrial HtrA2 (Omi, Prss25) is the best characterized and involved in programmed cell death (Li et al., 2002) and neuromuscular disorder (Jones et al., 2003). In contrast with HtrA2, the mammalian HtrA1 and its close family members, HtrA3 and HtrA4, are secreted proteins that contain an aminoterminal signal peptide, an insulin-like growth factor binding domain, and a Kazal-type serine protease inhibitor domain upstream of the HtrA homology region. HtrA1 (L56, Prss11) was originally isolated as a gene down-regulated in simian virus 40-transformed human fibroblasts (Zumbrunn and Trueb, 1996), and recent studies showed that HtrA1 is either absent or significantly downregulated in various tumors (Shridhar et al., 2002; Baldi et al., 2002; Chien et al., 2004). In addition, overexpression of HtrA1 inhibits proliferation and tumor growth and causes apoptosis, suggesting that HtrA1 is a candidate tumor suppressor. HtrA1 has also been implicated in osteoarthritis (Hu et al., 1998) and more recently in Alzheimer’s disease (Grau et al., 2005). More recently, a single nucleotide polymorphism in the HtrA1 promoter has been presented as a major risk factor for aged-
related macular degeneration (DeWan et al., 2006; Yang et al., 2006). HtrA1 binds to and inactivates members of the TGFβ family (Oka et al., 2004) and modulates insulin-like growth factor (IGF) signals (Hou et al., 2005), but its biological function is not yet known.

1.14  Aim of the study
We have recently identified the *Xenopus* homolog of HtrA1 (xHtrA1) in a direct screen for secreted proteins (Pera et al., 2005). Here, we introduce xHtrA1 as a novel modulator of FGF signalling that participates in axial development, mesoderm formation and neuronal differentiation. xHtrA1 is activated by FGF signals and induces ectopic *FGF4* and *FGF8* transcription. We could identify Biglycan, Syndecan-4 and Glypican-4 as proteolytic targets of xHtrA1 and show that pure heparan sulfate and dermatan sulfate phenocopy xHtrA1 and FGF activities in *Xenopus* embryos. The results suggest that xHtrA1 acts as a positive feedback regulator of FGF signals and through proteolytic cleavage of proteoglycans allows long-range FGF signalling in the extracellular space.
2. Materials and methods
2.1 Materials
2.1.1 Solutions

Human chorionic gonadotropin (HCG)
Resuspend in 5 ml dH2O to make a stock solution of 2000 U/ml, aliquot in fractions of 1 ml each, and store at –20 °C.

5 X MBS (Modified Barth Solution)
440 mM NaCl, 12 mM NaHCO₃, 5 mM KCl, 50 mM HEPES (pH 7.0), 4.1 mM MgSO₄, 2.05 mM CaCl₂, 1.65 mM Ca(NO₃)₂, adjust pH to 7.4.

L-Cystein hydrochloride 2%
10 g L-Cystein hydrochloride, dissolve in 500 ml ddH2O and adjust pH to 7.8 – 8.0

Ficoll 10%
10 g Ficoll in 100 ml ddH2O, filter through 45µl filter and store at 4 °C.

Injection buffer
1 % Ficoll in 1 X MBS,

10 X MEM
1 M MOPS, 20 mM EDTA, 10 mM MgSO₄ in 500 ml ddH₂O and autoclave

1 X MEMFA
10 ml 10 X MEM, 10 ml 37 % Formaldehyde in 80 ml ddH₂O

10x PBS
80 g NaCl, 2 g KCl, 14.4 g Na₂HPO₄, 2.4 g KH₂PO₄, dissolved in 800 ml distilled water, adjust pH to 7.4, add distilled water to 1 L and autoclave.

X-Gal staining solution
100 µl (0.1M) K₃Fe(CN)₆, 100 µl (0.1M) K₄Fe(CN)₆, 4 µl MgCl₂, 50 µl (40 mg / ml) XGal in DMSO in 1.75 ml PBS

Red-Gal staining solution
100 µl (0.1M) K₃Fe(CN)₆, 100 µl (0.1M) K₄Fe(CN)₆, 4 µl MgCl₂, 10 µl Red-Gal (40 mg / ml in DMSO) in 1.75 ml PBS

PBSw
PBS with 0.1% Tween-20
PBSw / Proteinase K solution

20 µl (20 mg / ml) Proteinase K in 20 ml PBSw

5 X MAB solution

500 mM Maleic acid, 750mM NaCl, adjust pH to 7.5 and autoclave.

20x SSC

175.3 g NaCl, 88.2 g sodium citrate, dissolve in 800 ml distilled water, adjust pH to 7.0, add distilled water to 1 L and autoclave.

Boehringer Block (BMB) 10 %

1 X MAB, 10 % BMB, dissolve at 60 °C and autoclave, then store at – 20 °C.

Hybridisation solution

10 g Boehringer block, 500 ml formamide, 250 ml 20x SSC, heat at 65 °C for 1 hour, 120 ml DEPC treated water, 100 ml Torula RNA (10 mg/ml filtered), 2 ml Heparin (50 mg/ml in 1xSSC), 5 ml 20 % Tween-20, 10 ml 10 %CHAPS, 10 ml 0.5 M EDTA.

Antibody buffer

10 % heat inactivated horse serum, 1 % Boehringer block, 0.1 % Tween-20, dissolve in PBS at 70 °C vortexing frequently.

AP buffer

100 mM Tris-HCl, pH 9.5, 50 mM MgCl2, 100 mM NaCl, 0.1 % Tween-20, prepare just before use.

Staining solution

NBT 1.75µl, BCIP 3.5µl per 1 ml AP buffer

Loading buffer

0.5 ml Tris-HCl (1 M pH7.5), 0.1 ml EDTA (0.5M), 0.025 % Bromophenol Blue, 0.025 % Xylenecyanol, 30 % Glycerol, add ddH2O to 50 ml

TE buffer

10mM Tris-HCl (pH7.5), 1m M EDTA, add ddH2O to 100ml and adjust pH to 8

Tris buffer (pH 9.5)

121.1 g Tris-HCl in 1 L ddH2O, adjust pH to 9.5 and autoclave

Diethylpyrocarbonat (DEPC) – dH2O

0.1 % Diethylpyrocarbonat, 500 ml dH2O, Incubate for 2 h at 37 °C and autoclave.
2.1.2 Media

Luria-Bertani (LB) medium:

20 g LB was dissolved into 1L ddH₂O and autoclaved for more than 20 min at 121°C, stored at 4°C.

Luria-Bertani (LB) agar plate:

1.5% (w/v) agar and 20 g LB were dissolved in 1 L sterile water and autoclaved for at least 20 min at 121°C then cooled to around 50°C before the antibiotic was added and the plates were poured in a sterile hood.

2.1.3 Kits

The following kits were used in this study, according to manufacturers instructions:

- SP6 Message Machine in vitro transcription Kit (Ambion)
- Qiagen Plasmid Midi Kit (Qiagen)
- QIAquick Purification Kit (Qiagen)
- QIAprep Spin Miniprep Kit (Qiagen)
- RNeasy Mini Kit (Qiagen)
- In vitro transcription Kit (Stratagene)
- Quickchange Site-directed Mutagenesis Kit (Stratagene)

2.1.4 Equipment

- Gastromaster (XENOTEK)
- TRIO Thermoblock (Biometra)
- Microinjector (Eppendorf)
- Pneumatic PicoPump PV820 (world Precision Instruments)
- PN30 needle puller (Narishige)

2.1.5 Experimental Organism

The African clawed frog *Xenopus laevis* was used as experimental organism during this study. Frogs were purchased from Nasco (Ft. Atkinson, USA). The embryonic staging was based on Nieuwkoop und Faber (1967).
2.1.6 Constructs

**pCS2+xHtrA1**
A full-length cDNA clone of xHtrA1 in pcDNA3 was obtained by secretion cloning (Pera et al., 2005). The xHtrA1 cDNA was then subcloned into the EcoRI/XhoI sites of the pCS2+ vector. For sense RNA synthesis, the construct was linearized with NotI and RNA transcribed with SP6 RNA polymerase.

**pBluescript II KS+ xHtrA1**
A full-length cDNA clone of xHtrA1 in pCS2+xHtrA1 was excised and cloned into the EcoRI/XbaI sites of pBluescript II KS+ vector. For antisense RNA synthesis, the construct was linearized with EcoRI and transcribed with T7 RNA polymerase.

**pCS2+ xHtrA1ΔGC**
The full-length sequence of pCS2+xHtrA1 without the CGCCSVC sequence was amplified with the forward primer (AflII) 5’-TTTCTTAAGAGCTGCTGCCGAGAATGAGCGCTGCG-3’ and reverse primer (Afl II) 5’-TTTCTTAAGGCCGTCTCCCCCGACTGGCAGTTG-3’. The PCR product was digested with Afl II and religated. For sense RNA synthesis, the construct was linearized with NotI and transcribed with SP6 RNA polymerase.

**pCS2+ xHtrA1ΔPDZ**
The open reading frame (ORF) of xHtrA1 lacking the PDZ domain was PCR-amplified with the forward primer (ClaI) 5’-AAAATCGATGTGCTGAGGACACAGAGG-3’ and reverse primer (XhoI) 5’-AAAATCGAGTTACTGCTGGTGTGCGACTC-3’ and cloned into the ClaI/XhoI sites of the pCS2+ vector. For sense RNA synthesis, the construct was linearized with NotI and transcribed with SP6 RNA polymerase.

**pCS2+xHtrA1Δtrypsin**
To generate pCS2-xHtrA1Δtrypsin (deletion of amino acids 151-343), the cDNA sequences upstream and downstream of the trypsin domain including the vector sequence of pCS2-xHtrA1 were PCR amplified using the forward primer (NheI) 5’-AAAAGCTAGCTGGGCTGCTGAGGG-3’ and reverse primer (NheI) 5’-AAAAGCTAGCTGGGCTGCTGAGGG-3’. The product was digested with NheI and religated. For sense RNA synthesis, the construct was linearized with NotI and RNA transcribed with SP6 RNA polymerase.

**pCS2+xHtrA1S307A**
For pCS2+xHtrA1S307A, a single point mutation was made in xHtrA1 to replace serine in
position 307 by alanine using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) with the forward primer 5’- TCAATTATGAAACGCTGGGGGCCCAGCTC-3’ and reverse primer 5’- GAGCGGGCCCCCAAGCGTTTCCATAATTGA-3’. For sense RNA synthesis, the construct was linearized with NotI and RNA transcribed with SP6 RNA polymerase.

**pCS2+xHtrA1**

To obtain pCS2-xHtrA1*, the xHtrA1 open reading frame (ORF) lacking the signal peptide was PCR-amplified with the forward primer (XhoI) 5’- AAAACTCGAGGCTCTCTTCTCCCCACATCC-3’ and reverse primer (XbaI) 5’- AAAATCTAGATTTAAAATTCTATTTCTTGGTG-3’ and cloned into the XhoI/XbaI sites downstream of the chordin signal peptide and Flag tag sequence of pCS2-Chd-Flag vector (gift of S. Piccolo, University of Padua, Italy). For sense RNA synthesis, the construct was linearized with NotI and RNA transcribed with SP6 RNA polymerase.

**pGEX-5X-1 xHtrA1-PDZ**

To generate the GST-tagged xHtrA1-PDZ construct, the PDZ domain of xHtrA1 (amino acids 344-481) was amplified by PCR with the forward primer (BamHI) 5’- AAAAGGATCCACAAACCAGCGTCACAGG-3’ and reverse primer (XhoI) 5’- AAAACTCGAGGAAACCAGGCTTCTCCATCC-3’ and cloned into the BamHI/XhoI sites of pGEX-5X-1 (Stratagene).

**pCS2+eFGF-GFP**

The ORF of Xenopus embryonic FGF (eFGF, FGF4) without stop codon (gift of J. Slack, University of Bath, UK) was amplified by PCR using the forward primer (BamHI) 5’- AAAAGGATCCATGACTGTCCATCGGC-3’ and reverse primer (XbaI) 5’- AAAATCTAGATTTCCCTGCGGACAAGAAATGG-3’, and inserted into the BamHI/XbaI sites of pCS2+Myc tag GFP (gift from Klymkowsky). For sense RNA synthesis, the construct was linearized with NotI and RNA transcribed with SP6 RNA polymerase.

**pCS2+FGF8-GFP**

The ORFs of Xenopus FGF8 without stop coden (gift of J. Slack, University of Bath, UK) was PCR amplified with the forward primer (ClaI) 5’- AAAATCGATGAAACTACATCACCTCCATC-3’ and reverse primer (XbaI) 5’- AAAATCTAGACCGAGAACTTTGAATATCGAG-3’ and inserted into pCS2+ Myc tag GFP vector. For sense RNA synthesis, the construct was linearized with NotI and RNA
transcribed with SP6 RNA polymerase.

**pCS2+ Flag FGF4**
The ORF without signal peptide of *Xenopus* FGF4 (gift of J. Slack, University of Bath, UK) was amplified with the forward primer (XhoI) 5’-AAACTCGAGCTGCGCTTTTTCCAGAG-3’ and reverse primer (XbaI) 5’-AAATCTAGATCATATCCGGCAAGAAATG-3’ and cloned into the XhoI/XbaI sites of the pCS2-chd-Flag vector (gift of S. Piccolo, University of Padua, Italy).

**pCS2+ Flag FGF8**
The ORF lacking the signal peptide of *Xenopus* FGF8 (gift of J. Slack, University of Bath, UK) was amplified with the forward primer (XhoI) 5’- AAACTCGAGCATGTGAGGGAGCAGAG-3’ and reverse primer (XbaI) 5’-AAATCTAGA CTACCGAGAACTTGAATATC-3’ and cloned into the XhoI/XbaI sites of the pCS2-Chd-Flag vector (gift of S. Piccolo, University of Padua, Italy).

**pCS2+ Flag Syn1**
The ORF of *Xenopus* Syndecan-1 (gift from J. Yost, University of Minnesota, U.S.A) lacking signal peptide was generated by PCR with the forward primer (SalI) 5’- AAAAGTCGAC GATGTGAGCGTGAGATCC-3’ and reverse primer (NheI) 5’- AAAAGCTAGC CTACGCGTAGAATTCCCGTGTGCACG-3’ and inserted into the XhoI/XbaI sites of the pCS2-Chd-Flag vector (gift of S. Piccolo, University of Padua, Italy) to introduce a chordin signal peptide and a Flag tag at the N-terminus of the mature syndecan1 protein.

**pCS2+ Flag Syn2**
The ORF of *Xenopus* Syndecan-2 (gift from J. Yost, University of Minnesota, U.S.A) lacking signal peptide was generated by PCR with the forward primer (XhoI) 5’- AAAACTCGAGCAAGCTGAGACAGACCTATATATC-3’ and reverse primer (XbaI) 5’- AAATCTAGATTACGCTAAAACTCTTTAG-3’ and inserted into the XhoI/XbaI sites of the pCS2-Chd-Flag vector (gift of S. Piccolo, University of Padua, Italy).

**pCS2+ Flag Bgn**
The ORF of *Xenopus* Biglycan (gift of J. Larrain, Universidad Catolica de Chile, Chile) lacking signal peptide was generated by PCR with the forward primer (SalI) 5’- AAAAGTCGACCTGCCTTTTGAAACAGAGG
-3’ and reverse primer (XbaI) 5’- AAATCTAGATTACTTCTCTGTAATTGCCAAAACGTG
-3’ and cloned into the XhoI/XbaI sites of the pCS2-Chd-Flag vector (gift of S. Piccolo, University of Padua, Italy). For sense RNA synthesis, the construct was linearized with NotI and transcribed with SP6 RNA polymerase.

**pCS2+ Flag Glypican4**

The ORF of *Xenopus* Glypican4 lacking the signal peptide was PCR-amplified with the forward primer (XhoI) 5’-AAACTCGAGATCTCAAGTCCAAGAGTTG-3’ and the reverse primer (XbaI) 5’-AAATCTAGATTATCTCCATTGCCTCACC-3’ and cloned into the XhoI/XbaI sites of the pCS2-chd-Flag vector (gift of S. Piccolo, University of Padua, Italy).

**pCS2+ Glypican-4 Flag**

The amino acids 1-539 of the *Xenopus* Glypican-4 ORF were amplified with the forward primer (EcoRI) 5’-AAAGATTTCCATGCTTGGATCTCCTTTTAC-3’ and reverse primer (XbaI) 5’-AAATCTAGA CTACTTGTCAATCGTCGTACTTGTAGTCAACACTGTTGGAAAGAGGCTG-3’ and cloned into the EcoRI / XbaI sites of the pCS2+ vector.

Other constructs, which have been used in this study, are as follows:

**pCS2+Flag Syn4** (provided by J. Larrain, Universidad Catolica de Chile, Chile.).

**pSP64T BMP4** (gift from W. Knöchel, University of Ulm, Germany). For mRNA synthesis, digested with BamHI and transcribed with SP6 RNA polymerase.

**pXFD/Xss** (gift from E. Amaya, Wellcome /CRC Institute, Cambridge, UK). For mRNA synthesis, digested with EcoRI and transcribed with SP6 RNA polymerase.

**pSP64T DN-FGFR4a** (gift from H. Okamoto, AIST Institute, Japan). For mRNA synthesis, digested with *SalI* and transcribed with SP6 RNA polymerase.

**nlacZ** mRNA from pXEXβgal (gift from R. Harland, University of California, Berkley, USA). For mRNA synthesis, digested with XbaI and transcribed with T7 RNA polymerase.

**pSP64T CFP-GPI** (gift from J. Smith, Wellcome /CRC Institute, Cambridge, UK). For mRNA synthesis, digested with EcoRI and transcribed with SP6 RNA polymerase.

**pBluescript KS Shh** For antisense RNA synthesis, digested with XbaI and transcribed with T3 RNA polymerase.
**pSP73-MyoD** For antisense RNA synthesis, digested with BamHI and transcribed with SP6 RNA polymerase.

**PCS2+GFP** For mRNA synthesis, digested with NotI and transcribed with SP6 RNA polymerase.

**pCS2+BFl** For antisense RNA synthesis, digested with XhoI and transcribed with SP6 RNA polymerase.

**pGEM-T-Rx2a** For antisense RNA synthesis, digested with NcoI and transcribed with SP6 RNA polymerase.

**pGEM-Krox20** For antisense RNA synthesis, digested with EcoRI and transcribed with T7 RNA polymerase.

**pGEM-3ZF-NKx2.5** For antisense RNA synthesis, digested with HindIII and transcribed with T7 RNA polymerase.

**pCDNA3-Sizzled** For antisense RNA synthesis, digested with BamHI and transcribed with SP6 RNA polymerase.

**pBS-SK-Otx2** For antisense RNA synthesis, digested with NotI and transcribed with T7 RNA polymerase.

**pSP73-Xbra** For antisense RNA synthesis, digested with BgIII and transcribed with T7 RNA polymerase.

**Sox2** For antisense RNA synthesis, digested with EcoRI and transcribed with T7 RNA polymerase.

**pGEM-Cytokeratin** For antisense RNA synthesis, digested with EcoRI and transcribed with SP6 RNA polymerase.

**Slug** For antisense RNA synthesis, digested with ClaI and transcribed with SP6 RNA polymerase.

**N-tubulin** For antisense RNA synthesis, digested with BamHI and transcribed with T3 RNA polymerase.

**pBS-ST-KS-En2** For antisense RNA synthesis, digested with XbaI and transcribed with T3 RNA polymerase.

**pBSII-KS+FGF4** For antisense RNA synthesis, digested with EcoRI and transcribed with T3 RNA polymerase.

**FGF8** For antisense RNA synthesis, digested with Xba and transcribed with T3 RNA polymerase.
2.1.7 Morpholino oligonucleotides

Morpholino antisense oligomers were obtained from Gene Tools Inc. and had the following sequences: \( xHtrA1 \)-MO 5’-ACACCGCCAGCCACAACATGGTCAT-3’ and standard control-MO 5’-CCTCTTACCTCAGTTACAATTTATA-3’. The morpholino oligomers were resuspended to 1 mM and further diluted in ddH\( _2 \)O to give a working solution, which was incubated at 65°C for 5 minutes before use.

2.2 Method

2.2.1 In vitro synthesis of sense RNA for microinjection

To prepare synthetic capped mRNA, the SP6 mMessage-mMachine™ Kit (Ambion) was used according to the manufacturer's protocol. A 20 µl reaction contains 1-1.5 µg linearized plasmid, 2 µl 10 x reaction buffer, 10 µl 2 x NTPs/Cap, 2 µl enzyme mix. Transcription was carried out at 37°C for 2.5 hours. The DNA template was removed by addition of 2 U DNaseI and incubated at 37°C for 30 min. The mRNA was purified with the RNeasy Mini Kit (Qiagen) accoding to the manufacture’s protocol, eluted in 20 µl RNase-free H\( _2 \)O. The concentration of mRNA was determined using the Nano drop ND-1000 (Nano Drop) and the quality assayed on an 1% agarose gel. mRNA was stored in aliquots at -20°C.

2.2.2 In vitro synthesis of antisense RNA for in situ hybridization

To prepare antisense RNA, a 25 µl reaction mixture was used that contains: 1-1.5 µg linearized template, 5 µl 5 x Transcription buffer (Fermentas), 2 µl 0.1 M DTT, 0.5 µl RNase out (Invitrogen), 1 µl RNA polymerase (Fermentas), 0.5 µl pyrophosphatase (Fermentas) and 4 µl Digoxigenin-Mix (5 µl 100 mM ATP, 5 µl 100 mM GTP, 5 µl 100 mM CTP, 3.25 µl 100 mM UTP, 17.25 µl Dig-11-UTP (Roche), 14.5 µl RNase-free H\( _2 \)O). The reaction was incubated at 37°C for 2.5 hours, and the DNA template was destroyed by adding 2 µl DNasel (Fermentas) and incubated at 37°C for 30 min. Antisense RNA probe was purified with the RNeasy Mini Kit (Qiagen) according to the manufacture’s protocol and eluted with 35 µl RNase-free H\( _2 \)O. The purified RNA probe was mixed with 30 µl formamide and 1150 µl hybridization solution and stored at -20°C. This antisense RNA probe was then diluted in hybridization solution according to the intensity of the in situ hybridization signals.
2.2.3 *Xenopus* embryo microinjection

Pigmented and albino *Xenopus laevis* frogs were purchased from Nasco (Ft. Atkinson, USA). Ovulation was stimulated by injection of 1000 IU human chorionic gonadotropin (hCG, Sigma) into the dorsal lymph sac of female frogs on the evening before egg collection. Eggs were fertilized *in vitro* with minced testes in 0.1 x MBS, dejellyed with 2% cystein hydrochloride (2% L-cystein hydrochloride in 0.1 x MBS, pH 7.8-8.0) and cultured in 0.1 x MBS buffer. Albino embryos were stained with Nile Blue sulphate (0.1 g Nile blue, 89.6 ml 0.5 M Na$_2$HPO$_4$, 10.4 ml NaH$_2$PO$_4$, filled to 1 L with ddH$_2$O, pH7.8). Embryos were staged according to Nieuwkoop and Faber (1967).

The microinjection needles were prepared from glass capillaries (Harvard apparatus, U.S.A) using the P-97 Flaming/ brown micropipette puller (Sutter instrument, U.S.A). The needles were back-filled using microloaders (Eppendorf). For the injection, a pneumatic PicoPump PV820 injector (Helmut Saur Laborbedarf, Reutlingen, Germany) was used. A volume of 4 nl for RNA or DNA and 10 nl for morpholino oligonucleotides was injected. Embryos were arranged on a glass slide in injection buffer (1% Ficoll, 1 x MBS). Following injection, the embryos were cultivated in injection buffer for 30-45 min and transferred into Petri dishes with 0.1 x MBS.

Embryos were fixed at the desired developmental stage in MEMFA (0.1 M MOPS, 2 mM EGTA (pH 8.0), 1 mM MgSO$_4$, 4% formaldehyde, pH7.4) overnight at 4 ºC. After fixation, the embryos were washed twice with 1 x PBS, dehydrated via the ethanol series in 1 x PBS (25% EtOH, 50% EtOH, 75% EtOH, 2x 100% EtOH) and stored in 100% EtOH at –20 ºC.

2.2.4 *Xenopus* explant assays and confocal microscopy

For the neural plate explant assay, *Xenopus* embryos were injected with 5 pg $xHtrA1$ mRNA into each blastomere at the 4-cell stage. When the embryos reached stage 13, neural plate explants together with underlying mesoderm and endoderm were excised in 0.8xMBS using the gastromaster (Xenotec), dissected into four sections roughly
corresponding to forebrain, midbrain, hindbrain and spinal cord, cultured until sibling embryos reached stage 28 and processed for RT-PCR (five explants per sample).

For the Einsteck experiment, dorsal marginal zone explants were isolated from \textit{xHtrA1} mRNA-injected stage 10.25 and \textit{xHtrA1}-MO injected stage 13 embryos in Steinberg solution (600 mM NaCl, 6.7 mM KCl, 3.4 mM Ca(NO$_3$)$_2$, 8.3 mM MgSO$_4$, 100 mM HEPES) and transplanted into the blastocoel cavity of stage 10.25 host embryos. After 1-2 hours of healing in Steinberg solution, transplanted embryos were transferred into 0.1xMBS and cultured until stage 42.

Animal cap conjugates were prepared and processed as described (Williams et al., 2004) with the modification that \textit{nlacZ} mRNA was used as lineage tracer. The \textit{Xenopus} embryos were microinjected with the indicated mRNAs into each blastomere at the 4-cell stage. In 0.8xMBS, animal cap explants from stage 8 embryos were dissected and juxtaposed in pairs with the inner sides facing each other. When sibling embryos reached stage 11, the animal cap conjugates were fixed in MEMFA solution at room temperature for 45 min and processed for X-gal staining. Subsequently, animal cap conjugates were re-fixed in MEMFA at 4ºC overnight, dehydrated through the ethanol series to 100% ethanol and stored at -20ºC before subjecting to \textit{in situ} hybridization with the \textit{Xbra} antisense probe.

For the confocal microscopy experiment, \textit{Xenopus} embryos were microinjected with \textit{FGF8-GFP}/\textit{FGF4-GFP} alone or in combination with \textit{xHtrA1} mRNA. Another group of embryos were injected with \textit{CFP-GPI} mRNA, Animal cap explants from injected embryos were dissected at stage 9.5-10.5 in 0.8xMBS and immediately transferred onto fibronectin-coated glass slides (Sigma, Gurdon et al., 1999). To allow stable contact between two adjacent caps, one small circular animal cap explant injected with FGF-GFP was surrounded by a second ring-shaped animal cap explant injected with \textit{CFP-GPI} mRNA. The tissue explants were overlaid with coverslips, with small pieces of broken glass slide as spacers in between glass plates and coverslips. Fluorescent signals were analyzed using a confocal laser scan Axiolpan2, LSM510 microscope (Zeiss, Germany).

In an independent experiment, GFP-labelled FGF8 protein was soaked in heparin bead (Sigma) and used as FGF ligand source. FGF8b recombinant protein (R&D; 1 mg) was
dissolved in 100 µl 0.1 M NaHCO₃, pH9.0. Alexa Fluor 488 fluorescent dye (Invitrogen; 0.2 mg) was dissolved in 20 µl DMSO. The fluorescent dye solution was slowly added into FGF8b protein solution. The mixture was incubated at room temperature for 2 hours on a shaker to allow binding of the fluorescent dye to the recombinant protein. In order to remove unbound fluorescent dye, the reaction mixture was transferred into Slide-A-Lyzer Mini dialysis units (Pierce) and dialyzed against 1x PBS (3 x 1 L, 4 ºC overnight in dark). The fluorescent dye-labelled FGF8b protein was stored in aliquots at -20 ºC. Heparin-acrylic beads (Sigma) were soaked in fluorescence-conjugated FGF8b proteins (30 min on ice) and used as carriers for FGF8b proteins. Animal cap explants injected with CFP-GPI alone or in combination with xHtrA1 were transferred to fibronectin-coated glass slides with the inner side facing upwards. After briefly washing away unbound proteins, an individual heparin bead was carefully transferred into a preformed hole at the center of the animal cap explant, and the conjugate was covered with a coverslip. Fluorescence signals were analysed using a con-focal laser scan microscope (Leica).

2.2.5 Whole mount in situ hybridization

The whole-mount in situ hybridization was performed as described (Hollemann et al., 1998) over a period of three days.

Day 1:
Embryos were rehydrated through the ethanol series (75%, 50%, 25% in PBS), 5 min for each step. Afterwards, embryos were washed with PTw (0.1% Tween-20 in 1x PBS, (4 x 5 min). Embryos were then digested with 0.5µl/ml Proteinase K (Sigma) in PTw (room temperature, 5-8 min). Subsequently, embryos were washed with 0.1M triethanolamine, pH7.5 (2 x 5 min) and acetylated by addition of 12.5 µl acetic anhydrite into 4 ml 0.1 M triethanolamine (2 x 5 min). Embryos were washed with PTw (2 x 5 min) and refixed with 4% formaldehyde in 1x PTw (room temperature, 20 min). Afterwards, embryos underwent wash steps as follows: PTw (5 x 5 min); 1.25 ml of 80% PTw, 20% hybridization mix; 500 µl hybridization mix (65 ºC, 10 min); 1 ml hybridization mix (65 ºC, 5 hours). Embryos were then hybridized overnight at 65 ºC in 1 ml hybridization solution containing the appropriate amount of antisense probe.

Day 2:
The probe/hybridization mix was removed, stored at -20° for later use, and replaced with 1 ml hybridization mix (60 °C, 10 min). Embryos were then washed with 4 ml of 2 x SSC (pH 7.0) at 60 °C, 3 x 15 min. Unspecifically bound antisense probe was digested by RNase Mix (10 µl/ml RNase A, 0.01 u/ml RNase T1 in 2x SSC) at 37 °C, 30-60 min. Embryos underwent the following processes: 2x SSC (10 min); 0.2x SSC (60 °C, 2 x 30 min); 1x MAB (2 x 15 min); 2% BMB in 1x MAB (20 min); 2% BMB, 20% horse serum in 1x MAB (60 min); 1/5000 anti-digoxigenin- alkaline phosphatase conjugated antibody (Sigma), 2% BMB, 20% horse serum in 1x MAB (4 hours); 1x MAB (3 x 10 min); 1x MAB (4 °C, overnight).

Day 3:
Embryos underwent several washing steps: 1x MAB (5 x 5 min); APB (100 mM Tris, pH 9.0; 50 mM MgCl₂; 100 mM NaCl; 0.1% TWEEN-20) (4 °C, 2 x 5 min).
Two different protocols for the staining reaction were applied. First, APB was substituted with an NBT/BCIP solution (1.75 µl/ml NBT (Fermentas), 3.5 µl/ml BCIP (Fermentas) in APB) Alternatively, embryos were washed with 0.1M Tris (pH 8.2) for 2 x 15 min and incubated with Fast Red (Roche; 1 tablet / 2 ml) in 0.1M Tris (pH8.2). Embryos were incubated on ice under dark conditions, until the desired staining was reached. The staining reaction was stopped by directly exchanging the staining solution with methanol. Subsequent exchange against fresh methanol helped to lower the background. Embryos were then transferred through a methanol series (75%, 50%, 25%, 5 min each step) and stored in MEMFA solution at 4 °C.

2.2.6 RT-PCR
Fifteen animal caps or 3 whole embryos were harvested in 400 µl Trizon (Invitrogen). Tissues were homogenized by first pipetting up and down using 1000 µl- and then 200 µl-pipet tips, followed by vortexing . At this step, the samples could be frozen at -20 °C. The tissues were thawed and vortexed again for 30 seconds, then 80 µl chloroform was added. The mixture was vortexed for 30 seconds and centrifuged in a table centrifuge at maximum speed (13,000 rpm) for 15 min at 4 °C. The upper phase was recovered and transferred into a new microfuge tube. Sebsequently, 200 µl chloroform was added and centrifuged for
5 min. The upper phase solution was transferred again into a new eppendorf tube and mixed with 200 µl isopropanol, after precipitated at -20 ºC for 30 min. Total RNAs were centrifuged down at maximum speed at 4 ºC for 30 min. The pellet was washed with 400 µl 75% ethanol. After centrifuge for 5 min, ethanol was removed and the pellet was dried. The RNA was eluted in 30 µl, 60 ºC pre-heated elution buffer.

The reverse transcriptase-polymerase chain reactions (RT-PCR) was used to analyze the gene expression level in embryonic explants or whole embryos. A standard 10 µl reverse transcription reaction consisted of: 2 µl 25 mM MgCl₂, 1 µl 10 x PCR buffer II (QBiogene), 1 µl 10 mM dATP, 1 µl 10 mM dGTP, 1 µl 10 mM dCTP, 1 µl 10 mM dTTP, 0.5 µl Random Hexamer (50 ng/µl, Invitrogen), 0.4 µl Reverse Transcriptase (Invitrogen), 0.2 µl RNase out (Invitrogen), 1.5 µl 30 ng/µl RNA, 0.4 µl DEPC water. RT reaction follows the Perkin Elmer protocol: 22 ºC, 10 min; 42 ºC, 50 min; 99 ºC, 5 min. A standard 25 µl of PCR reaction contained 5 µl cDNA obtained from RT reaction, 0.5 µl 25 mM MgCl₂, 2µl 10x PCR buffer II, 0.75 µl gene specific primer (forward and reverse, 7.5µM each), and 0.1 µl Taq polymerase (5 u/µl, QBiogene) and 16.75 µl HPLC water. PCR program was designed as follows: pre-denaturation at 94 ºC for 2 min, 28 cycles of denaturation at 94ºC for 45 sec, annealing at 56 ºC for 45 sec and extension at 72 ºC for 45 sec, followed by final extension at 72 ºC for 5 min.

The following primers, annealing temperatures and cycle numbers were used: Histone H4 (forward primer 5’-CGGGATAAACATTCAGGGGTACTA and reverse primer 5’-CATGGCGGTAACTTCTTCTC-3’, 56 ºC, 24 cycles); Xbra (forward primer 5’-GGATCGTTATCACCTCTC-3’ and reverse primer 5’-GTGTAGTCTGTACAGCAGCTGCTGATC-3’, 56ºC, 28 cycles); xHtra1 (forward primer 5’-TGTTGTGGCTGGCGGTGTCTTACTG-3’ and reverse primer 5’-TCCATCCTCCGACACAATACTGCC-3’, 57ºC, 43 cycles); Rx2a (forward primer 5’-CAACAGCCCAAGAAGAAACACAG-3’ and reverse primer 5’-GAGGGCAGTCCGAGCAGAAGG-3’, 56ºC, 28 cycles); Otx2 (forward primer 5’-CCAGTCATCTCGAGCAGACA-3’ and reverse primer 5’-CAGGAGCGTTGCTGCTTTTG-3’, 56ºC, 28 cycles); Kroxa20 (forward primer 5’-CGCCCCAGTAAGACC-3’ and reverse primer 5’-TCAGCCTGTCTTGTTAG-3’, 56ºC,
30 cycles); *HoxD1* (forward primer 5’-CAGCCCCGATTACGATTATTATGG-3’ and reverse primer 5’-CCGGGAGGCGAGGGTTTCTGAG-3’, 56°C, 30 cycles); *HoxB9* (forward primer 5’-GCCCTGCGCAATCTGAAC-3’ and reverse primer 5’-CAGCAGCGCTCAGACTTGAG-3’, 56°C, 28 cycles); *Xcad3* (forward primer 5’-GGATCACCGAGGGAGGAATG-3’ and reverse primer 5’-TAAGAGCGCTGGGTGAGTTGG-3’, 56°C, 28 cycles). The PCR products were separated on 2% agarose gels.

### 2.2.7 Cell culture and transfection

HEK293 cells were split, stored and cultured according to product sheet (Invitrogen). At 50-60% confluency, cells were transfected. Plasmid DNA (3 µg) of substrate candidate constructs such as Flag-Biglycan, Flag-Syndecan4 and Glypican4-Flag alone or together with xHtrA1 DNA (2.5 µg) were added into 250 µl DMEM with 2 mM L-glutamine. One tenth of pAdvantage plasmid DNA was added to increase transfection efficiency (Pera et al., 2005). Add 2.5 µl lipofectamine 2000 (invitrogen)/ per µg DNA into another 250 µl DMEM with L-glutamine and incubate at room temperature for 5 min. These above two solutions were then mixed well and incubated at room temperature for 20 min. In 6-well plate, the culture medium was exchanged with 2 ml DMEM with L-glutamine, 10% Horse serum. The DNA and lipofectamine complexes were then added and mixed well. One day afterwards, culture medium was substituted with 1 ml DMEM with 2 mM L-glutamine. Three days after transfection, cells were harvested with cell scrapers and lysed in 200 µl RIPA buffer on ice.

### 2.2.8 Antibody production and immunopurification

pQE32-His-xHtrA1-PDZ and pGST-xHtrA1-PDZ were electroporated into SG1300 (Qiagen) and BL21 bacteria (Stratagene), respectively. Expression of recombinant protein was induced with 1 mM IPTG in LB medium containing 50 µg/ml carbenicillin. After 6 hours incubation at 220 rpm and 30°C, the bacteria were spun down at 6000 rpm and 4°C for 10 minutes and frozen at -80°C. The bacterial pellet was then thawed and resuspended on ice in lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% glycerol, 0.4% Triton-X-100, 0.1 mM PMSF, complete EDTA-free protease inhibitor cocktail (Roche)) and sonicated for 20 minutes with Sonifier 450 (G. Heinemann). The
bacterial lysate was centrifuged at 10,000 rpm at 4°C for 30 minutes and the supernatant was harvested for purification.

His-tagged xHtrA1-PDZ was purified under native conditions with Ni-NTA Agarose (Qiagen) and GST-tagged xHtrA1-PDZ was purified using Glutathione immobilized on cross-linked 4% beaded agarose (Sigma) according to the manufacturer’s protocols. Polyclonal antibodies against the recombinant xHtrA1-PDZ proteins were independently raised in rabbits (Bioscience, Göttingen). The pre-serum and immunized serum from the third bleeding was subjected to immunoaffinity purification using the AminoLink Plus Immobilization Kit (Pierce). The concentration of IgG was measured with the Bradford reagent (Sigma).

2.2.9 Whole mount immunohistochemistry with pH3 and dpERK

Whole-mount immunostaining was done using the protocol modified from Christen and Slack, 1999; Saka and Smith, 2001) using anti-phosphorylated histone3 (pH3, 1:200, Upstate Biotechnology) and anti-phospho-p44/42 MAP Kinase, Thr202/Tyr204 (dpERK, 1:200, Cell Signaling). Goat anti-rabbit antibody coupled with alkaline phosphatase (1:2000; Sigma) was used as secondary antibody.

Embryos were transferred from ethanol to methanol, and kept in Dents solution (80% methanol, 20% DMSO) at -20 °C overnight. Embryos were rehydrated through methanol series (100%, 75%, 50%, 25%, 5 min each step), washed with 1x PBS (2 x 10 min). The vitelline membranes were removed by digesting with 0.5 µl/ml Proteinase K in PBS (room temperature, 5-8 min) and the reaction was stopped by washing with 1x PBS (2 x 5 min). Unspecific binding was blocked by incubating embryos with 20% horse serum in 1x PBS (room temperature, 2 hrs). Embryos were incubated with appropriate dilution of 1st antibody in 20% horse serum, 1x PBS (room temperature, 5 hrs). Unbound antibody was washed through series steps: PBS-TB (0.05% Tween-20, 0.2% BSA in 1x PBS) (2 x 2 hrs); PBS-TBN (0.3 M NaCl in PBS-TB) (2 hrs); PBS-TB (5 min). Then embryos were incubated with the 1/2000 dilution of 2nd antibody in 20% horse serum in 1x PBS (5 hrs). After several wash steps: PBS-TB (2 x 30 min); PBS-TBN (30 min); PBS-TB (3 x 10 min), APB (2 x 5 min, 4 °C), embryos were incubated in color reaction solution (1.75
µl/ml NBT, 3.5µl/ml BCIP in APB) (4 °C in dark). The background of staining was removed by washing with methanol for several times.

2.2.10 Immunoblotting
For immunoblotting, embryo lysates were prepared as described (Pera et al., 2003). Proteins were separated by 12% SDS-PAGE and Western blots performed using purified polyclonal antibodies against xHtrA1-PDZ (1:400) and GAPDH (1:2500, Abcam). Goat anti-rabbit antibody coupled with horseradish peroxidase (1:10,000; Cell Signaling) was used as secondary antibody.

2.2.11 Dermatan sulfate preparation (done by Prof. Dr. Anders Malmström and Dr. Marco Maccarana)
Bovine lung dermatan sulfate was prepared by precipitation with cetylpyridium chloride in 0.5 M NaCl. The crude polysaccharide was further purified by repetitive precipitation as copper complex (Stern et al., 1968). To be certain that heparin and heparan sulfate would not be present as contaminants, deamination at pH 1.5 (Shively and Conrad, 1976) was performed and dermatan sulfate reisolated after ethanol precipitation. The absence of heparin/heparan sulfate was confirmed by lacking of 232 nm absorbance following extensive heparinase treatment.

2.2.12 Proteoglycan isolation and lyase treatment (done by Dr. Marco Maccarana)
Proteoglycan were extracted at 4°C from embryos adding 5 volumes of guanidine extraction buffer (50mM acetate pH 5.5, 4M guanidine/HCl, 10 mM EDTA, 2% Triton X-100, DTT 1mM, PMSF 1 mM, aprotinin, leupeptin, pepstatin, each at 1 µg/ml) and homogenizing by Potter. The homogenate was diluted 1:20 with buffer A (50 mM acetate pH 5.5, 6M urea, 1mM EDTA, 0.1% Triton X-100, DTT 1mM, PMSF 1 mM, aprotinin, leupeptin, pepstatin, each at 1 µg/ml) and applied to 1 ml DE52 anion-exchange column, operated at 4°C. The column was washed with buffer A containing 0.1M NaCl, and eluted with 10 volumes of buffer (2M acetate pH 5.5, 6M urea, 1mM EDTA, 0.1% Triton X-100, DTT 1mM, PMSF 1 mM, aprotinin, leupeptin, pepstatin, each at 1 µg/ml). Proteoglycans were precipitated by addition of 4 volumes of ethanol, re-precipitated with ethanol, 1.4% Na-Acetate, liophilized, and finally re-dissolved in TBS, containing 0.1% Triton X-100,
DTT 1mM, PMSF 1 mM, aprotinin, leupeptin, pepstatin, each at 1 µg/ml. Soluble material after 20,000g X 30 min was used for lyase treatment and Western blot analysis.

Twenty µl of the above anion-exchange purified material was diluted 1:3 with Tris 20 mM pH 7.5, NaCl 50 mM, CaCl2 4 mM, followed by addition of 0.5 mU Chondroitinase B (Seikagaku, Japan), or mock-treatment. After overnight incubation at 37°C, the reaction was stopped by Laemmli buffer, and the samples were subjected to Western blot analysis on pre-made 4-12% acrylamide mini-gel (NuPAGE, Invitrogen). Flag-Biglycan was decorated by anti-Flag antibody HRP-conjugated (1:1000; Sigma, A8592), and detected by ECL (AmershamBioscience, Sweden).

2.2.13 Paraffin section
Embryos were fixed in MEMFA solution (room temperature, 1 hour), washed in 1 x PBS (3 x 5 min) and then gradually transferred into 100% ethanol for storage. For paraffin embedding, embryos were transferred to chloroform and then to xylene (2 x 20 minutes). Subsequently, embryos were incubated in 60°C melting paraffin (2 x 1 hour) and then embedded in paraffin. A microtome was used to prepare 10 µM tissue sections and fixed onto glass slides. Let the section slides dry on 40°C heater for overnight.

2.2.14 Hematoxylin eosin staining
Embryonic section slides was washed with xylene (2 x 5min), and then transferred gradually through ethanol gradient series (100%, 2 x 3 min; 95%, 3 min; 70%, 3 min) into distilled water (3 min). The sections were stained in Hematoxylin solution (10 sec). The excessive staining was washed away first by tap water (2 x 10 shakes), then by Scott’s tap water (10 g MgSO4, 2 g NaHCO3 in 1 L ddH2O; 2 min), followed by ddH2O (2 min). The section slides were transferred into 70% ethanol (3 min) and stained with eosin solution (50 mg eosin Y, 350 µl glacial acetic acid in 100 ml 95% ethanol; 3-5 min). The sections were then washed with 95% ethanol until unspecific staining being removed. The slides underwent decreasing concentration of ethanol series to 1 x PBS and then can be mounted in Mowiol solution (5 g Mowiol, 10 ml glycerol in 20 ml PBS, pH~7.0. Not dissolved Mowiol removed by centrifugation).
3. Results

3.1 Identification of Xenopus HtrA1

We isolated a full-length cDNA clone of Xenopus HtrA1 (xHtrA1) by secretion cloning from UV-ventralized gastrula embryos (Pera et al., 2005). xHtrA1 was identified as a 50 kD secreted protein in the supernatant of transfected and metabolically labeled human embryonic kidney (HEK) 293T cells (data not shown). The xHtrA1 cDNA clone (GenBank accession number EF490997) encompasses a 303 bp 5’ untranslated region (5’ UTR), a 1379 bp open reading frame (ORF) followed by a 109 bp 3’ UTR. At its amino terminus, predicted by Psort software (http://psort.nibb.ac.jp), Xenopus HtrA1 (xHtrA1) has a 16 amino acids cleavable signal peptide. The mature protein contains an IGF binding domain, a Kazal-type serine protease inhibitor domain, a trypsin-like serine protease domain and a PDZ (PSD95/DlgA/ZO-1 homology) protein-protein interaction domain (Fig. 1; Hou, 2004). xHtrA1 homologues also exist in human (68% amino acid identity; Zumbrunn and Trueb, 1996; Hu et al., 1998), mouse (68% amino acid identity; Oka et al., 2004) and have the same modular composition as xHtrA1. In addition, related proteins are found in Drosophila melanogaster (46% amino acid identity) and Escherichia coli (40% amino acid identity; Lipinska et al., 1990), that share a signal peptide, a trypsin domain and one (Drosophila) or two copies (E. coli) of the PDZ domain.

Figure 1. Protein structure of Xenopus HtrA1

Schematic structures of xHtrA1 and related homologues. The GenBank accession numbers for the listed proteins are Xenopus HtrA1 (EF490997), human HtrA1 (NP 002766), mouse HtrA1 (AAH13516), Drosophila serine protease (NP 650366) and E. coli HtrA/DegP (X12457). The positions of signal peptides (SP) are predicted by PSORT II program (http://psort.nibb.ac.jp) and the domain annotations derived from NCBI Conserved Domain Search. IB, Insulin-like growth factor binding domain; K, Kazal type serine protease inhibitor domain; Typsin, trypsin-like serine protease domain and PDZ, PSD95 (post synaptic density protein) DlgA (Drosophila disc large tumor suppressor) ZO1 mammalian tight junction protein domain. The numbers indicate the percentages of amino acid identity with the corresponding domains in xHtrA1. Figure modified from Hou, 2004.
3.2 Expression of xHtrA1

We analysed the expression of xHtrA1 in early Xenopus embryos (Fig. 2). Reverse transcription polymerase chain reaction (RT-PCR) analysis showed that xHtrA1 gene transcripts were not detected in unfertilized eggs or embryos younger than mid-blastula transition (MBT), indicating that xHtrA1 is not maternally expressed (Fig.2A). xHtrA1 gene transcripts were detected in early and mid gastrula stage (stage 10 and 11). The expression of xHtrA1 reached its peak at late gastrula (stage 12) and early neurula (stage 13). Subsequently, xHtrA1 gene expression decreased at open neural plate stage (stage 14 and 15) and then enhanced again at mid neurula stage (stage 16). The transcripts were too weak to be observed at tadpole stage (stages older than 20).

Whole mount in situ hybridization at the early gastrula stage (stage 10) revealed ubiquitous expression of xHtrA1 in the ectoderm and mesoderm but not endoderm (Fig. 2B). Since the yolk in the vegetal part of the embryo may quench in situ hybridization signals, RT-PCR analysis was performed on ectodermal, mesodermal and endodermal explants of stage 10 embryos (Fig. 2C,D). xHtrA1 transcripts exhibited highest levels in mesoderm and intermediate levels in ectoderm, but only very weak expression in endoderm explants (Fig. 2D), confirming the result of the whole mount in situ hybridization (Fig. 2B). As gastrulation proceeded, distinct expression was seen in a ring around the blastopore with higher intensity in the dorsal mesoderm (Fig. 2E). In late gastrula embryos, this periblastoporal expression domain became located to the posterior end, while an additional expression domain appeared in the anterior neural plate (Fig. 2F). During neurulation, xHtrA1 expression further strengthened in the rostral CNS exhibiting high levels in the prospective eye field and in bilateral spots at the level of the midbrain-hindbrain boundary, at this stage, a new expression domain appeared in the neural folds (Fig. 2G). At the tail bud stage, transcripts were restricted to neural crest-derived cells of the facial mesenchyme and branchial arches (Fig. 2H and data not shown).

The expression pattern of xHtrA1 shows similarities to sites of FGF signaling in the early embryo (Christen and Slack, 1997; 1999; Fig. 2I-L). Overlapping expression domains with FGF8 include the blastopore ring (Fig. 2I), anterior neural plate, early midbrain-hindbrain
boundary, posterior mesoderm (Fig. 2J,K), and the branchial arch region (Fig. 2L). In addition, the expression of \textit{xHtrA1} matches with ERK activation in the neural folds (Christen and Slack, 1999).

Figure 2. Gene expression of \textit{Xenopus HtrA1}

(A) RT-PCR analysis of \textit{xHtrA1} transcripts in the unfertilized egg and whole embryos. Staging of embryos according to Nieuwkoop and Farber (1994). \textit{Histone4 (H4)} was used as RNA loading control. Note abundant \textit{xHtrA1} expression during the gastrula and neurula stages. (B) Lateral view of a hemi-sectioned early gastrula embryo (stage 10) after whole mount \textit{in situ} hybridization with antisense \textit{xHtrA1} RNA probe. (C) Diagram of stage 10 embryo dissected into ectoderm (ec), mesoderm (me), and endoderm (en). (D) RT-PCR analysis of embryo explants from (C). \textit{xHtrA1} transcripts are abundant in ectoderm and mesoderm but hardly detectable in endoderm. (E-L) Whole mount \textit{in situ} hybridization of \textit{xHtrA1} (E-H) and \textit{xFGF8} (I-L). \textit{Xenopus} embryos at late gastrula stage, (E,I; dorso-vegetal view), early neurula stage (F,J; dorsal view), mid-neurula stage, (G,K; anterior view), tailbud stage (H,L; lateral view). The arrowhead indicates the midbrain-hindbrain boundary; bpl, blastopore lip; anp, anterior neural plate; pm, posterior mesoderm; nf, neural fold; fb, forebrain; ba, branchial arch.

3.3 Regulation of \textit{xHtrA1} transcription by FGF signals

An animal caps experiment was performed to test the regulation of \textit{xHtrA1} expression by FGF signaling (Fig. 3A). To this end, synthetic mRNAs of \textit{Xenopus FGF8} and \textit{FGF4} (also called \textit{embryonic FGF, eFGF}) were microinjected into the animal pole of each
blastomere of the four-cell stage embryo. Animal caps were excised from stage 9 blastula embryos and cultured until sibling embryos reached stage 18. RT-PCR was performed to assay endogenous \( xHtrA1 \) transcription and mesodermal \( Xbra \) gene expression was used as control. Uninjected animal caps neither expressed \( xHtrA1 \) nor \( Xbra \) (Fig. 3A, lane 2). Injection of \( FGF8 \) mRNA upregulated \( xHtrA1 \) transcription in a concentration dependent manner (Fig. 3A, lane 3-5). In the same explants, \( Xbra \) gene transcription was induced at low dose of \( FGF8 \) and downregulated at higher dose of \( FGF8 \) (Hardcastle et al., 2000). \( xHtrA1 \) was also upregulated in animal caps injected with \( FGF4 \) mRNA (Fig. 3A, lanes 6-8), concomitant with a robust activation of \( Xbra \) (Isaacs et al., 1999). The activation of \( xHtrA1 \) by members of the FGF family was specific, as \( BMP4 \) mRNA failed to induce \( xHtrA1 \) (Fig. 3A, lane 9), even though a dosage of \( BMP4 \) mRNA was injected that robustly induced \( Xbra \) expression.

We also tested whether FGF signaling is required for \( xHtrA1 \) transcription, using marginal zone explants from gastrula embryos (Fig. 3B). Four-cell stage embryos were microinjected into the marginal zone of each blastomere with different doses of mRNAs encoding a dominant negative FGF receptor-4a (DnFGFR4a; Hongo et al., 1999) or dominant negative FGFR-1 (XFD; Amaya et al., 1991). At stage 10, marginal zone regions were dissected and cultured for 2 hours, until sibling embryos reached stage 11. Marginal zone explants from uninjected embryos showed robust expression of \( xHtrA1 \) and \( Xbra \) (Fig. 3B, lane 2). However, microinjection of DnFGFR4a or XFD mRNAs did not reduce \( xHtrA1 \) mRNA levels, even at doses that significantly lowered or completely erased \( Xbra \) expression (Fig. 3B, lanes 3-6). We conclude that FGF signaling is sufficient, but not required for \( xHtrA1 \) transcription. The overlapping expression between \( xHtrA1 \) and \( FGF8 \) sites and the finding that \( xHtrA1 \) is activated by FGF signals suggest that \( xHtrA1 \) may belong to the \( FGF8 \) synexpression group.
Figure 3. FGF is sufficient, but not required to induce xHtrA1

(A) Four-cell stage embryos were injected into the animal pole of each blastomere with FGF8 mRNA (50, 150, 450 pg per embryo), FGF4 mRNA (3, 6, 12 pg per embryo) or BMP4 mRNA (200 pg per embryo). Animal cap explants were cut from stage 9 embryos and analyzed at stage 18 by RT-PCR for expression of xHtrA1 and Xbra. (B) Four-cell stage embryos were injected into the marginal zone of each blastomere with DnFGFR4a mRNA (400 pg, 4 ng per embryo) or XFD mRNA (2 ng, 6 ng per embryo). Marginal zone explants were excised from stage 10 embryos, and analyzed at stage 11 by RT-PCR for gene expression.

3.4 xHtrA1 blocks head formation and induces ectopic tails in a non-cell autonomous manner

To investigate the activity of xHtrA1, synthetic mRNA was injected into the animal pole of one ventral blastomere at the four-cell stage (Fig. 4; Hou, 2004). Embryos were first analyzed at the early tailbud stage, when the pigmentation of the closing neural folds demarcates the anteroposterior body axis (Fig. 4A). Microinjection of xHtrA1 mRNA caused an overall shortening of the embryo and formation of a secondary body axis (Fig. 4B). Interestingly, the xHtrA1-induced ectopic axis was fused with the primary axis at the anterior end of the embryo. This phenotype is clearly distinct from a secondary axis induced by ventral injection of Wnt/β-Catenin signals or BMP antagonists, which converges with the primary embryonic axis at the posterior end (Moon and Kimelman, 1998). At the swimming tadpole stage, injection of xHtrA1 mRNA caused the loss of head structures, including cement gland and eyes, and induced the formation of ectopic tail-like outgrowths (Fig. 4C,D; Hou, 2004). The induced tails consisted of dorsal and ventral fins also found in the primary tails. Histological analyses of xHtrA1-injected embryos showed that the secondary tail-like structures contained spinal cord, notochord and somite tissue (Fig. 4E). A single injection of xHtrA1 mRNA induced ectopic expression of the neuronal marker N-tubulin (Fig. 4F,G; Hou, 2004), the axial marker Sonic Hedgehog (Fig. 4H,I; Hou, 2004) and the paraxial mesoderm marker MyoD (Fig. 4J,K; Hou, 2004) at sites where secondary axes formed. These findings indicate that the supernumerary tail structures induced by xHtrA1 misexpression are of high complexity and contain all elements characteristic of endogenous tails. To determine whether xHtrA1 can induce ectopic structures on neighboring cells, we used the green fluorescent protein (GFP) as a lineage marker. After co-injection of xHtrA1 and GFP mRNA into one ventral blastomere, GFP-positive cells were found predominantly in the secondary tail region (25%; Fig.
Injection of xHtrA1 and GFP mRNA into one dorsal blastomere also generated secondary tail-like structures (11%; Fig. 4M,M’), albeit with lower frequency. Interestingly, the ectopic tail outgrowths were devoid of any GFP expression, suggesting that xHtrA1 recruited non-injected neighboring cells into the induced structures. The results demonstrate that xHtrA1 has non-cell autonomous activity and signals at long-range in the embryo.

Figure 4. xHtrA1 induces ectopic tail-like structures in a non-cell autonomous way

(A) An uninjected tailbud embryo in dorsal view, anterior to the left. (B) Sibling embryo injected with 80 pg xHtrA1 mRNA into one ventral blastomere at the four-cell stage. Note the secondary axis (arrowhead) fused with the primary body axis at the anterior end (21/88). (C) Uninjected embryo at swimming tadpole stage. (D) Reduction or loss of head structures (186/203) and ectopic tails (61/203; arrowhead) induced by a single ventral injection of xHtrA1 mRNA. (E) Histological section of xHtrA1-injected embryo; secondary spinal cord (sc), notochord (nc) and somites (so) can be seen. (F-K) Ectopic expression domains of N-tubulin (differentiated neurons; 15/18), Shh (axial midline; 3/15), and MyoD (paraxial mesoderm; 6/19) induced by xHtrA1 mRNA in tailbud (F,G; lateral view) and neurula embryos (H-K; dorsal view). Note that ectopic gene expression (arrowheads) in (I) and (K) arises adjacent to cells co-injected with xHtrA1 and nuclear lacZ mRNA (red nuclei). (L,L’,M,M’) Lineage tracing of xHtrA1 mRNA-injected cells using green fluorescent protein (GFP). Tailbud stage embryos in bright and darkfield views (merged pictures, L,M) or darkfield view alone (L’,M’). (L,L’) After a single ventral injection of xHtrA1 and GFP mRNA, injected cells populate the ectopic tail structure (arrowhead; 3/12). (M,M’) Co-injection of xHtrA1 and GFP mRNA into one dorsal blastomere induces ectopic tail outgrowths (arrowhead) distant to the injection site.
Amounts of mRNA injected per blastomere were xHtrA1 (80 pg), nlacZ (50 pg), GFP (320 pg). Panels C-D, F-K as in Hou, 2004. Master Thesis.

3.5 Proteolytic activity is required for xHtrA1 effects

To investigate the role of individual domains in the HtrA1 protein, a series of mutant constructs were generated and studied in Xenopus embryos (Fig. 5A; Hou, 2004). Microinjection of wild type xHtrA1 mRNA into one ventral blastomere at the four-cell stage caused anencephaly and secondary tail formation in embryos at the advanced tail bud stage (Fig. 5C; Hou, 2004). The IGF binding domain of xHtrA1 contains a consensus CGCCXXC sequence (X, variable amino acid), characteristic of most members of the Insulin-like growth factor binding protein (IGFBP) superfamily. A deletion mutant lacking this consensus sequence (xHtrA1ΔGC) caused anencephaly and ectopic tail formation at a frequency similar to the wild type xHtrA1 (Fig. 5D), indicating that the CGCCXXC sequence is not crucial for the xHtrA activity. Next, the entire trypsin-like serine protease domain was deleted (xHtrA1Δtrypsin). Microinjection of xHtrA1Δtrypsin mRNA gave rise to normally developed embryos (Fig. 5E), indicating that trypsin domain may be essential for the xHtrA1 activity. Since the trypsin domain comprises nearly two fifth of the mature protein, its deletion may change the overall conformation or interfere with a possible oligomerization of the protein. It has been reported that a mutational alteration of the active site serine to alanine in E. coli HtrA/DegP and in human HtrA1 results in loss of the proteolytic activity (Skorko-Glonek et al., 1995; Hu et al., 1998). We therefore substituted in xHtrA1 the catalytic serine at position 307 with alanine (xHtrA1S307A). Microinjection of xHtrA1S307A mRNA failed to show any effect (Fig. 5F; Hou, 2004), suggesting that the proteolytic activity is required for the activity of xHtrA1. The PDZ protein-protein interaction domain has been shown to bind to substrates of mouse HtrA1 and thereby regulates its proteolytic activity (Murwantoko et al., 2004). A PDZ deletion mutant (xHtrA1ΔPDZ) failed to exhibit anencephalic or tail-like outgrowth phenotype caused by wild type xHtrA1 (Fig. 5G), demonstrating the requirement of PDZ domain.

To ensure that the wild type and mutant proteins were properly synthesized in vivo, we performed a Western blot analysis of lysates from uninjected and mRNA-injected embryos at the late blastula stage (Fig. 5H), using an immunopurified antibody against the carboxyterminal PDZ domain of the xHtrA1 protein (see Materials and Methods). This
analysis showed that wild type $xHtrA1$, $xHtrA1\Delta GC$, $xHtrA1\Delta trypsin$ and $xHtrA1S307A$ generated comparative amount of proteins of the expected size (Fig. 5H and data not shown). We therefore rule out the possibility that the control-like phenotype from proteolytic domain mutants was due to failure of protein synthesis, concluding that the activity of xHtrA1 depends on the integrity of a functional proteolytic domain.

Figure 5. The proteolytic and the PDZ domain are required for the activity of xHtrA1

(A) Schematic diagram of wild type and mutant xHtrA1 protein constructs. (B) Uninjected tailbud embryo. (C) Loss of head structures (111/124) and secondary tail-like outgrowths (44/124) after injection of 80 pg $xHtrA1$ mRNA into one ventral blastomere at the four-cell stage. (D) Anencephaly (43/54) and ectopic tail formation (16/54) induced by 80 pg $xHtrA1\Delta GC$ mRNA. (E-G) Embryos injected with 80 pg mRNA of $xHtrA1\Delta trypsin$ (E, n=406), $xHtrA1 S307A$ (F, n=280) or $xHtrA1\Delta PDZ$ (G, n=86) show normal axial development. (H) Western blot analysis of wild type and mutant xHtrA1 proteins. Embryos were injected at the four-cell stage with 800 pg mRNA of the indicated

3.6 Effects of xHtrA1 on embryonic patterning
To study the effects of xHtrA1 on pattern formation, we performed whole mount in situ hybridization with region- and tissue-specific molecular markers. At the early gastrula stage, Otx2 has two distinct expression domains demarcating the anterior ectoderm (prospective cement gland, forebrain and midbrain) and the anterior mesendoderm (prechordal plate) (Fig. 6A; Hou, 2004). HtrA1 mRNA blocked the anterior ectoderm domain of Otx2, but did not affect its mesendodermal expression (Fig. 6B; Hou, 2004). The pan-mesodermal marker Xbra demarcates the marginal zone of the gastrula stage embryo (Fig. 6C; Hou, 2004). HtrA1 greatly expanded Xbra expression into the animal hemisphere (Fig. 6D; Hou, 2004), indicating that xHtrA1 may transform ectoderm into mesoderm. At the onset of neurulation, BF1 demarcates the anterior-most part of the neural plate, which differentiates to the prospective telencephalon (Fig. 6E; Hou, 2004), Rx2a labels the eye field and Krox20 indicates rhombomeres 3 and 5 of the hindbrain (Fig. 6G; Hou, 2004). xHtrA1-injected embryos failed to express BF1, Rx2a and Krox20 gene expression (Fig. 6F,H; Hou, 2004). Nkx2.5 marks pre-cardiac mesoderm (Fig. 6 I; Hou, 2004) and Sizzled is expressed in the heart and ventral blood islands (Fig. 6K; Hou, 2004). HtrA1 blocked expression of the heart markers Nkx2.5 and ventral mesoderm marker Sizzled in the anterior part of the embryo (Fig. 6J,L; Hou, 2004). Notably, HtrA1 expanded the expression domain of Sizzled in the ventroposterior mesoderm (Fig. 6L; Hou, 2004). Hence xHtrA1 suppresses anterior brain and heart development and promotes posterior mesoderm formation.
Whole mount \textit{in situ} hybridization of embryos after microinjection of \textit{nlacZ} mRNA as control or \textit{xHtrA1} mRNA into one blastomere at the four-cell stage. (A) Early gastrula embryo (dorsolateral view) with \textit{Otx2} expression in the interior ectoderm (arrowhead) and anterior mesendoderm (star). (B) A single animal injection of \textit{xHtrA1} mRNA (160pg) blocks expression of \textit{Otx2} in the anterior ectoderm (45/45). (C) Sibling embryo (lateral view) with \textit{Xbra} expression in the marginal zone. (D) A single marginal injection of \textit{xHtrA1} (160 pg) expands \textit{Xbra} expression into the animal hemisphere (20/23). (E) Mid-neurula stage embryo (anterior view) with \textit{BF1} expression demarcating the telencephalon. (F) Animally injected \textit{xHtrA1} mRNA blocks expression of \textit{BF1} (22/23). (G) Sibling embryo (anterior view) with \textit{Rx2a} labeling the prospective eye field and \textit{Krox20} rhombomeres 3 and 5 of the hindbrain. (H) Animally injected \textit{xHtrA1} mRNA (160 pg) blocks expression of \textit{Rx2a} (16/20) and \textit{Krox20} (6/20). (I) Late neurula (ventral view) with \textit{Nkx2.5} demarcating the presumptive heart. (J) Animally injected \textit{xHtrA1} leads to loss of \textit{Nkx2.5} expression (28/36). (K) Mid-neurula (ventral view) with \textit{Sizzled} expression in the heart (arrowhead) and ventral mesoderm (star). (L) Marginal injection of \textit{xHtrA1} (80 pg) reduces \textit{Sizzled} signals anteriorly, but expands \textit{Sizzled} gene activity at the posterior end of the embryo (31/36). Panels A-L are from Hou, 2004. Master Thesis.

3.7 \textit{xHtrA1} has posteriorizing effect on antero-posterior neural patterning

We further investigated the effects of \textit{xHtrA1} on pattern formation of the central nervous system. To this end, we excised the neural plate plus underlying mesoderm and endoderm from late gastrula embryos and subdivided the tissue into four sections roughly corresponding to the future forebrain, midbrain, hindbrain and spinal cord (Fig. 7A). The explants were grown \textit{in vitro} until sibling embryos reached the tailbud stage and analyzed by RT-PCR using region-specific molecular markers (Fig. 7B,C). The most anterior portion of the neural plate (section 1) normally expresses the forebrain marker \textit{Rx2a} and the forebrain/ midbrain marker \textit{Otx2}, but not the hindbrain marker \textit{Krox20} (Fig. 7B; lane 2). After microinjection of \textit{xHtrA1} mRNA into animal pole of each blastomere of four-cell stage embryos, the equivalent region of the neural plate showed reduced \textit{Rx2a} and \textit{Otx2} expression, but activation of the hindbrain marker \textit{Krox20} (Fig. 7B; lane 3). The more
posterior section II from uninjected neural plate normally expresses *Otx2*, but not the posterior hindbrain/ spinal cord marker *HoxD1* (Fig. 7B; lane 4). *xHtrA1* injection led to a loss of *Otx2* expression and de novo induction of the more posterior marker *HoxD1* (Fig. 7B; lane 5). Section III usually is positive for *Krox20* expression, but negative for more posterior spinal cord marker *HoxB9* (Fig. 7B; lane 6). In the presence of *xHtrA1*, the counterpart section lost *Krox20* expression, but induced the more posterior spinal cord marker *HoxB9* instead (Fig. 7B; lane 7). In section IV, expression of *HoxD1* and *HoxB9* was not affected by *xHtrA1* injection (Fig. 7B; lanes 8 and 9). The results indicate that *xHtrA1* shifts the overall anteroposterior neural markers anteriorly (Fig. 7C), suggesting that *xHtrA1* exerts posteriorizing activity onto the neural plate.

Figure 7. *xHtrA1* posteriorizes the neural plate

(A) Experimental design. After injection of *Xenopus* embryos with *xHtrA1* mRNA into the animal pole of each blastomere at the four-cell stage (20 pg total per embryo), embryos were cultured in 0.1 x MBS until siblings reached early neurula stage (stage 13). The neural plate plus underlying mesoderm and endoderm was excised and four sections roughly corresponding to forebrain, midbrain, hindbrain and spinal cord were cultured in 0.8 x MBS. (B) RT-PCR analysis of explants (n=5 per sample) at equivalent of embryonic stage 26 with region-specific neural markers. *Rx2a*, forebrain; *Otx2*, forebrain/midbrain;
Krox20, rhombomeres 3 and 5 of the hindbrain; HoxD1, caudal to rhombomere 4 of the hindbrain and spinal cord; HoxB9, spinal cord; H4, histone4 for normalization. Note that sections I-III progressively lose anterior and gain posterior marker gene expression after xHtrA1 mRNA injection, while section IV remains unaffected. (C) Regional fate of neural plate in uninjected and xHtrA1-injected embryos at stage 13 according to RT-PCR analysis at stage 26. Note the anteriorward shift of molecular markers in response to xHtrA1 mRNA.

3.8 xHtrA1 dorsalizes the ectoderm and induces neuronal differentiation

Our studies so far focused on the influence of xHtrA1 on anteroposterior development and mesoderm induction of the embryo. Does this molecule also affect ectoderm patterning along the dorsoventral axis? The loss of head structures and the repression of anterior brain markers suggested that xHtrA1 may interfere with neural plate development. Surprisingly, microinjection of xHtrA1 mRNA caused significant expansion of the pan-neural marker Sox2 towards the anterior and lateral side of early neurula embryos (Fig. 8A,B; Hou, 2004). Concomitantly, the neural crest marker Slug was severely reduced or lost (Fig. 8C,D; Hou, 2004) and the epidermal marker Cytokeratin was ventro-laterally displaced (Fig. 8E,F). At the mid-neurula stage, xHtrA1 induced supernumerary N-tubulin-positive neurons, scattered throughout the epidermis on the lateral and ventral side of the embryo (Fig. 8G,H; Hou, 2004). In sum, xHtrA1 expands the neural plate at the expense of neural crest and epidermis development, and promotes neurogenesis to occur.

Figure 8. Effects of xHtrA1 on ectodermal patterning

Whole mount in situ hybridization analysis of embryos following a single animal injection of nlacZ mRNA (control) or xHtrA1 mRNA at the four-cell stage. (A-F) Early neurula stage embryo in dorsal view. xHtrA1 mRNA causes anterior and lateral expansion of Sox2 (A,B, 62/67), reduction of Slug (C,D, 19/30) and Cytokeratin (E,F, 9/9) expression. (G,H) Mid-neurula embryo in dorsal view. xHtrA1 mRNA induces ectopic expression of N-tubulin (G,H, 34/49) in the lateral and ventral parts of the embryo. Panels A-D, G-H are from Hou, 2004. Master Thesis.
3.9 xHtrA1 affects cell migration and promotes cell division

To further study the behaviour of xHtrA1-injected cells, we used GFP as a lineage tracer. Microinjection of GFP mRNA into one dorsal animal blastomere at the eight-cell stage targets cells in the anterior region and along the dorsal midline of the neural plate (Fig. 9A,A’). The dynamics of GFP labeling in early neurula stage embryos reflects the convergence extension movements characteristic for neural plate cells at this stage (Elul et al., 1998 and data not shown). When co-injected with xHtrA1 mRNA, GFP-positive cells of the neural plate remain more distant to the dorsal midline (Fig. 9B,B’ and data not shown). The failure of xHtrA1-injected cells to reach their proper location indicates that xHtrA1 may affect morphogenetic movements.

We next investigated the effect of xHtrA1 on proliferation, using an antibody against phosphorylated Histone3 (pH3, Saka and Smith, 2001) in whole mount embryos. Microinjection of xHtrA1 mRNA into one animal blastomere at the eight-cell stage did not change the number of pH3-positive nuclei on the dorsal side (Fig. 9C,D). However, the same injection caused a two-fold increase of pH3-labelled cells on the ventral side (Fig. 9E,F,G), indicating that xHtrA1 promotes mitotic activity. In sum, xHtrA1 affects the behaviour of cells in numerous ways including perturbation of cell migration and stimulation of cell proliferation.
Figure 9. Effects of xHtrA1 on cell migration and proliferation

(A–B’) Early neurula embryos in dorsal view after injection of 230 pg GFP mRNA into one dorsal blastomere at the four-cell stage. Embryos are shown in bright and darkfield views (merged pictures, A,B) or darkfield views alone (A’,B’). Note that cells co-injected with 80 pg HtrA1 mRNA do not converge towards the midline, but remain in a more distal position (arrowhead). A minimum of 30 embryos has been analyzed. (C–F) Immunostaining for phosphorylated Histone3 (pH3) in early neurula embryos. Note that a single animal injection of HtrA1 mRNA does not change the number of proliferating cells on the dorsal side, but increases cell proliferation on the ventral side. (G) Quantification of pH3-positive cells per embryo. For each sample, 3 specimens were evaluated.

3.10 xHtrA1 is essential for proper axial development, mesoderm formation and neuronal differentiation

In order to investigate the endogenous function of xHtrA1, we used an antisense morpholino oligonucleotide to specifically interfere with the protein biosynthesis of xHtrA1 in Xenopus embryos (Fig. 10). We designed a 25-mer morpholino sequence against the translation initiation site of the isolated xHtrA1 gene and a related xHtrA1 pseudoallele (xHtrA1-MO; Fig. 10A). Western blot analysis using an anti-xHtrA1 polyclonal antibody showed that the xHtrA1-MO efficiently blocked synthesis of the xHtrA1 protein, whereas a non-specific control morpholino (Co-MO) had no effect on xHtrA1 protein production (Fig. 10B, lanes 1-3). The specificity of the xHtrA1-MO was
further demonstrated by its inability to reduce the protein level of a recombinant \textit{xHtrA1} construct that is not targeted by the \textit{xHtrA1-MO} (\textit{xHtrA1*}; Fig. 10B, lanes 4 and 5). In \textit{xHtrA1*}, the aminoterminal signal peptide of \textit{xHtrA1} has been replaced by a heterologous signal peptide from the Chordin protein followed by a Flag tag sequence (see Materials and methods). The data indicate that \textit{xHtrA1-MO} is an efficient and specific tool to reduce \textit{xHtrA1} protein expression. Microinjection of 8 pmol control-MO into the animal pole at the two-cell stage had no effect compared to non-injected embryos (Fig. 10C and data not shown). In contrast, injection of the same account of \textit{xHtrA1-MO} led to a remarkable reduction of the full body length and enlargement of the head (Fig. 10D; as in Hou, 2004). At the tadpole stage, \textit{xHtrA1-MO} caused reproducibly enlargement of the head, reduction of the eye size and significantly shortened tail (Fig. 10E,F; as in Hou, 2004).

To further examine the effects of the \textit{xHtrA1-MO}, molecular markers were analyzed by whole mount \textit{in situ} hybridization. Strikingly, in gastrula embryos, marginal injection of the \textit{xHtrA1-MO} blocked expression of the pan-mesoderm marker \textit{Xbra} (Fig. 10G,H). In neurula embryos, animally injected \textit{xHtrA1-MO} reduced expression of \textit{N-tubulin} (Fig. 10I,J). \textit{xHtrA1-MO} also erased the posterior expression domain of the ventral mesoderm marker \textit{Sizzled} (Fig. 10K,L; as in Hou, 2004). The effect of the \textit{xHtrA1-MO} was reverted by co-injection of \textit{xHtrA1*} mRNA (Fig. 10N). The phenotype of the \textit{xHtrA1-MO} is opposite to those observed in gain-of-function experiments (Figs. 6D,L and Fig. 8H) and suggest an \textit{in vivo} requirement of \textit{xHtrA1} for restricting the head territory and allowing tail structures, mesoderm and neurons to form.
Figure 10. A morpholino oligonucleotide against xHtrA1 enhances anterior development and impairs mesoderm and neuronal differentiation

(A) An antisense morpholino oligonucleotide against xHtrA1 (xHtrA1-MO) targets sequences of both Xenopus laevis HtrA1 alleles (GenBank accession numbers are EF490997 and BC087471.1). (B) Western blot to verify the efficiency and specificity of the xHtrA1-MO. Embryos were microinjected at the two-cell stage with 8 pmol xHtrA1-MO or an unspecific control morpholino oligonucleotide (Co-MO), followed by 320 pg mRNA injection at the 4-cell stage of wild-type xHtrA1 (xHtrA1) or of a recombinant xHtrA1 clone that is not targeted by the xHtrA1-MO (xHtrA1*). Extracts from blastula stage embryos were analyzed by Western blotting, using an immunopurified polyclonal anti-xHtrA1 antibody (α-xHtrA1) to detect the xHtrA1 protein. An anti-Glyceraldehyde-3-phosphate dehydrogenase antibody (α-GAPDH) was used as protein loading control. Note that protein synthesis of xHtrA1 is completely blocked by xHtrA1-MO (lanes 1 and 2) and largely unaffected by the Co-MO (lane 3). xHtrA1-MO does not reduce synthesis of the non-targeted xHtrA1* construct (lanes 4 and 5). (C) Tailbud stage embryo injected animally with a total of 8 pmol control-MO at the two-cell stage (92/92). (D) Microinjection of 8 pmol xHtrA1-MO results in reduction of the body length and enlargement of the head territory (60/60). (E) A control-MO-injected tadpole embryo (18/18). (F) A sibling xHtrA1-MO-injected embryo has enlarged head, reduced eyes and significantly shortened tail structures (51/51). (G) Early gastrula in lateral view after whole mount in situ hybridization with Xbra. A single marginal injection of 10 pmol control-MO and 50 pg nlacZ mRNA as lineage tracer (red nuclei) has no defect on Xbra expression (17/19). (H) Sibling embryo injected with 10 pmol xHtrA1-MO and 50 pg
nlacZ mRNA exhibits a gap in the Xbra expression domain at the injected site (red nuclei, 22/28). (I) Mid-neurula embryo in dorsal view labeled with N-tubulin. A single animal injection of 10 pmol control-MO and 50 pg nlacZ mRNA has no obvious effect on N-tubulin expression (15/19). (J) Sibling embryo injected with 10 pmol xHtrA1-MO and 50 pg nlacZ mRNA diminishes N-tubulin expression on the injected side (16/18). (K-N) Mid-neurula stage embryos in ventral view after in situ hybridization with Sizzled antisense probe. (K) A non-injected neurula stage embryo exhibits Sizzled expression at the anterior and posterior end of the embryo (L) Microinjection of 8 pmol xHtrA1-MO abolishes the posterior expression domain of Sizzled (41/47). (M) A control-MO shows no effect (19/19). (N) Microinjection of 80 pg xHtrA1* mRNA at the four-cell stage reverts the loss of Sizzled posterior expression caused by xHtrA1-MO (15/15). Panels C-F, K-L are similar to those in Hou, 2004. Master Thesis.

3.11 A neutralizing antibody against xHtrA1 anteriorizes embryonic development

As an independent test for the requirement of xHtrA1 in axial development, we made use of a neutralizing antibody, which recognizes the PDZ domain of xHtrA1, to block the activity of xHtrA1 in the extracellular space (Fig. 11). Microinjection 100 nl of purified pre-immune serum into the blastocoel cavity of a blastula stage embryo had no detectable effect (Fig. 11B). In contrast, microinjection of the immuno-purified antibody anti-xHtrA1 resulted in an anteriorized phenotype. Typically, the body axis was shortened and the head enlarged at the expense of trunk and tail structures at the advanced tail bud stage (Fig. 11C). The specificity of this effect was underscored by the finding that the anteriorized phenotype of the anti-xHtrA1 antibody was rescued by co-injection of xHtrA1 mRNA (Fig. 11D). Together the data support a function of xHtrA1 in normal development of the anteroposterior body axis.

Figure 11. Blastocoel injection of an anti-xHtrA1 antibody promotes anterior development (A) Uninjected tail bud embryo. (B) Injection of 100 nl of immunopurified pre-serum has no effect (114/121). (C) Enlarged head structures after injection of 100 nl immunopurified
anti-xHtrA1 antibody (α-xHtrA1, 200 ng) into the blastocoel at stage 8 (32/107). (D) Microinjection of 160 pg xHtrA1 mRNA into blastomeres of the four-cell stage blocks the anteriorizing effect caused by blastocoelic injection of α-xHtrA1 (5/5).

3.12 HtrA1 cooperates with FGF signals

The phenotypic effects observed in xHtrA1 mRNA-injected embryos are reminiscent of those caused by FGF signals. Microinjection of FGF4 DNA into one ventral blastomere of four-cell stage embryos resulted in the induction of secondary posterior outgrowths that developed into complex tail-like structures (Fig. 12A; Pownall et al., 1996); radially injected FGF4 mRNA caused expansion of the mesoderm marker Xbra into the animal hemisphere (Fig. 12B; Pownall et al., 1996); FGF8 mRNA triggered ectopic N-tubulin-positive neuronal differentiation (Fig. 12C, Hardcastle et al., 2000). To test whether xHtrA1 and FGFs also cooperate during mesoderm induction, we performed an animal cap assay (Fig. 12D-H). We injected mRNA encoding FGF4 and xHtrA1 either alone or in combination into the animal pole of four-cell stage embryos, excised animal caps at the blastula stage and cultured them in vitro, until sibling embryos reached the tailbud stage. While uninjected control caps formed spherical structures containing epidermis (Fig. 12D), few caps elongated when injected with xHtrA1 mRNA (Fig. 12E) or a suboptimal dosis of FGF4 mRNA (Fig. 12F), indicating formation of mesoderm tissue. Strikingly, co-injection of both FGF4 and xHtrA1 mRNA caused a dramatic elongation of all animal caps (Fig. 12G). To confirm mesoderm induction at the molecular level, we analyzed the mesodermal markers Xbra and Xcad3 by RT-PCR analysis when sibling embryos reached the mid-gastrula stage (Fig. 12H). Uninjected animal cap explants showed no Xbra and Xcad3 expression (Fig. 12H, lane 2). Microinjection of xHtrA1 mRNA mildly activated the expression of Xbra and Xcad3, giving support to the notion that xHtrA1 induces mesoderm differentiation. As expected, FGF4 mRNA also activated these mesodermal marker genes (Fig. 12F, lane 4; Pownall et al., 1996). Importantly, co-injection of xHtrA1 and FGF4 mRNA further enhanced Xbra expression, indicating that xHtrA1 stimulates mesoderm induction by FGF4 (Fig. 12F, lane 5). The results clearly show a cooperative effect between HtrA1 and FGF signals during mesoderm induction.
Figure 12. Effects of FGFs on embryonic development and cooperation with xHtrA1 during mesoderm induction

(A) Tadpole embryo with ectopic tail-like outgrowth (arrowhead) induced by microinjection of 4 pg FGF4 DNA into one ventral blastomere at the four-cell stage (13/66). (B) Significant expansion of the mesoderm marker Xbra induced by 1.6 pg FGF4 mRNA injection into each animal blastomere at the four-cell stage (23/23). Insert shows un.injected sibling embryo. (C) Ectopic N-tubulin-positive neurons induced by microinjecting 5 pg FGF8 mRNA into a single animal blastomere at the four-cell stage (118/120). (D-G) Embryos were injected with mRNA of xHtrA1 and FGF4 either alone or in combination, animal caps were excised at stage 8 and cultured until stage 25. (E) Animal caps extend only very slightly when injected with 360 pg xHtrA1 mRNA. (F) A suboptimal dosage of FGF4 mRNA (3.2 pg) causes mild elongation in some animal explants. (G) A combination of xHtrA1 and FGF4 mRNA showed robust elongation in all animal caps. (H) RT-PCR of animal cap explants at stage 11.

3.13 Role of FGF signals for the activity of xHtrA1

xHtrA1 and FGFs show similar activities in axial development, mesoderm induction and neuronal differentiation. They exhibit cooperative effects on mesoderm induction in animal cap explants. These observations suggest that xHtrA1 and FGF signaling may be linked. To test whether FGF signals are required for the actions of xHtrA1, endogenous FGF signaling was blocked by dominant negative FGF receptor constructs. We used truncated version of the FGFR1 (XFD) and FGFR4a (DnFGFR4a), that each contain an intact extracellular and transmembrane domain, but lack an intracellular tyrosine kinase domain (Amaya et al., 1991; Hugo et al., 1999). Microinjection of XFD mRNA enlarged head structures at the expense of trunk and tail development (Fig. 13B, Amaya et al., 1991). Notably, XFD blocked the loss of head structures and formation of ectopic tail-like...
protrusions in embryos co-injected with xHtrA1 mRNA (Fig. 13C,D). These results suggest that intact FGF signaling is crucial for the effects of xHtrA1 on anterior-posterior axis formation. FGF signals also play a role in mesoderm formation, as shown by the suppression of Xbra expression by XFD mRNA injection (Fig. 13E,F; Amaya et al., 1991). Importantly, XFD abolished ectopic Xbra expression induced by xHtrA1 (Fig. 13G,H), suggesting that FGF signaling is important for xHtrA1-mediated mesoderm induction. An involvement of FGF signals in the formation of differentiated neurons is evident from the loss of N-tubulin expression by DnFGFR4a mRNA (Fig. 13 I,J; Hardcastle et al., 2000). While xHtrA1 mRNA induced ectopic neurons on both the injected and non-injected contralateral side (Fig. 13K), neurogenesis by xHtrA1 was blocked by co-injection of DnFGFR4a on the injected side (Fig. 13L). In conclusion, multiple patterning activities of xHtrA1 including anterior-posterior patterning, mesoderm formation and neuronal differentiation, rely on intact FGF signaling pathway.

Figure 13. xHtrA1-mediated posteriorization, mesoderm induction and neuronal differentiation require intact FGF signaling

(A) Uninjected tadpole. (B) Microinjection of 110 pg XFD mRNA into the animal pole of four-cell stage embryos causes enlargement of head structures and slight shortening of the body length (54/68). (C) Anencephaly and ectopic tail-like outgrowth induced by a single ventral injection of 80 pg xHtrA1 mRNA (68/80 with reduced heads, 32/80 with ectopic tail-like protrusions). (D) Restoration of head development and suppression of ectopic tail
formation after co-injection of 110 pg XFD and 80 pg xHtrA1 mRNA (13/16). (E) Uninjected embryo at early gastrula stage (lateral view) after whole mount in situ hybridization with an Xbra antisense probe. (F) Blockage of endogenous Xbra expression by a radial injection of 220 pg XFD into one blastomere at the four-cell stage (38/47). nlacZ mRNA (100 pg) was co-injected as a lineage tracer (red nuclei). (G) Ectopic Xbra expression induced by a single marginal injection of 80 pg xHtrA1 mRNA (13/13). (H) Co-injection of 220 pg XFD mRNA inhibits ectopic Xbra expression induced by xHtrA1 mRNA (16/18). (I) Uninjected embryo at mid-neurula stage (dorsal view) after whole mount in situ hybridization with N-tubulin demarcating trigeminal ganglion cells, motor neurons, intermediate neurons and sensory neurons. (J) Suppression of endogenous N-tubulin expression by injection of 110 pg DnFGFR4a mRNA into one blastomere at the four-cell stage (18/18). (K) Microinjection of 80 pg xHtrA1 mRNA induces ectopic N-tubulin expression (10/12). Note that supernumerary neurons are not restricted to the injected side (red label), but arise in a non-cell autonomous manner on the contra-lateral side. (L) Co-injection of DnFGFR4a and xHtrA1 mRNA inhibits ectopic N-tubulin expression on the injected side (10/10).

3.14 xHtrA1 activates FGF signaling

To investigate whether xHtrA1 directly affects FGF activity, we analysed the activation of the FGF signaling intermediate ERK (extracellular signal regulated protein kinase) by immunoblotting (Fig. 14A). Microinjection of xHtrA1 mRNA led to an accumulation of diphosphorylated ERK (dpERK; Fig. 14A, lanes 1,2). Compared to control-MO which did not show any effect, the xHtrA1-MO blocked ERK phosphorylation (Fig. 14A, lanes 3,4), indicating a requirement for xHtrA1 in the activation of FGF signaling. Whole-mount immunostaining showed that in gastrula embryos, the double phosphorylated form of ERK (dpERK) was restricted to the marginal zone (Fig. 14B; Christen and Slack, 1999). Radial injection of xHtrA1 mRNA led to expansion of dpERK signals into the animal hemisphere (Fig. 14C). Co-injection of XFD not only eliminated endogenous dpERK, but also prevented expansion of dpERK signals by xHtrA1 (Fig 14D). Whole mount in situ hybridization showed that in neurula embryos, microinjection of xHtrA1 induced ectopic FGF8 and FGF4 transcription (Fig. 14E,F,H,I). The ability of xHtrA1 to activate ectopic FGF gene activity was blocked by co-injection of XFD or DnFGFR4a mRNA (Fig. 14G,J). This finding suggests that xHtrA1 stimulates ERK phosphorylation and the expression of FGF8 and FGF4 via FGF receptor signaling. Based on these and previous data (Fig. 3A), we conclude that xHtrA1 and FGF form a positive feedback loop, in which each component reinforces the gene activity of the other (Fig. 14K).
3.15 xHtrA1 stimulates FGF signaling at distance

We next studied whether xHtrA1 promotes long-range FGF signaling using an animal cap conjugate assay. Animal caps from embryos injected with FGF4, xHtrA1 and nlacZ mRNA as lineage tracer (“inducer” caps) were first combined with un.injected “responder” caps, incubated in vitro for 4.5 hours and analyzed by in situ hybridization for Xbra expression (Fig. 15A, upper half). Control conjugates injected with nlacZ mRNA alone
were flat and did not express *Xbra* (Fig. 15B). Following microinjection of *FGF4* mRNA, the responding hemisphere slightly elongated and showed weak *Xbra* expression restricted to the interface with the inducer hemisphere (Fig. 15C). *xHtrA1* mRNA on its own exhibited only a little effect, with slight elongation of animal cap conjugates but without detectable *Xbra* expression (Fig. 15D). However, when *xHtrA1* was in combination with *FGF4* mRNA, it triggered a robust outgrowth of both the inducer and the responder caps. Importantly, the levels of *Xbra* expression were greatly elevated and expanded to locations far away from the sites of FGF4 secretion (Fig. 15E). In an independent experiment, we examined how signaling was affected, when the sources of FGF4 and xHtrA1 were spatially segregated. We recombined *FGF4* mRNA-injected inducer caps with *xHtrA1* mRNA-injected responder caps (Fig. 15A, lower half). *nlacZ*-injected control inducer caps combined with *xHtrA1*-treated responder caps induced only slight elongation without *Xbra* staining (Fig. 15F). In contrast, juxtaposition of *FGF4* and *xHtrA1* sources triggered elongation of both hemispheres and resulted in strong and widespread *Xbra* expression (Fig. 15G). The fact that *nlacZ*-labeled cells from the inducer cap did not intermingle with responder cap cells indicates that the effect of xHtrA1 was not due to cell movements. The results demonstrate that xHtrA1 stimulates long-range signaling of FGF.

Figure 15. xHtrA1 promotes long-range FGF signaling in the animal cap conjugate assay
(A) Experimental design. “Inducer“ animal cap explants from blastula stage embryos were injected with 16 pg $FGF4$ alone or in combination with 160 pg $xHtrA1$ mRNA and juxtaposed to un.injected „responder“ animal caps (upper panel). Alternatively, an $FGF4$-injected inducer cap was recombined with an $xHtrA1$-injected responder cap (lower panel). The inducer caps were co-injected with 100 pg $nlacZ$ mRNA as lineage tracer (blue X-Gal staining) to distinguish them from the responder caps. The animal cap conjugates were cultured for 4.5 hours at room temperature until sibling embryos reached the mid-gastrula stage, fixed and analyzed by whole-mount in situ hybridization for the expression of the FGF-responsive $Xbra$ gene (orange staining). (B) Control animal cap conjugates with $nlacZ$-injected inducer cap (blue) and uninjected responder cap remain flat and do not express $Xbra$. (C) Slight elongation and narrow $Xbra$ expression (red) in the responder cap at the interface to the $FGF4$-injected inducer cap. (D) $xHtrA1$ in the inducer cap does not cause significant elongation and detectable $Xbra$ expression in the responder cap. (E) A combination of $FGF4$ and $xHtrA1$ induces significant elongation and robust $Xbra$ expression in the responder cap. (F) $xHtrA1$ in the responder cap has no apparent effects on the conjugate. (G) $xHtrA1$ in the responder cap juxtaposed to an $FGF4$-injected inducer cap causes strong elongation and $Xbra$ expression far away from the signaling source.

3.16 $xHtrA1$ causes proteolytic degradation of Biglycan, Syndecan4, and Glypican4

Proteoglycans are important regulators of FGF signaling that control the spread and activity of FGF ligands in the extracellular space (Trowbridge and Gallo, 2002; Kramer and Yost, 2003). It has previously been reported that an aminoterminally truncated mouse HtrA1 construct consisting of only the trypsin and PDZ domains degrades bovine Biglycan (Tocharus et al., 2004). *Xenopus* Biglycan ($xBgn$) as well as the heparan sulfate proteoglycans Syndecan4 ($xSyn4$) and Glypican4 ($xGpn4$) are expressed in the early embryo (Galli et al., 2003; Moreno et al., 2005; Munoz et al., 2006). We transfected full-length $xHtrA1$ cDNA together with Flag-tagged $xBgn$, $xSyn4$, and $xGpn4$ constructs into HEK293 cells. Western blot analysis showed that $xHtrA1$ caused degradation of all three proteoglycans (Fig. 16A). In order to confirm this result in vivo in *Xenopus* embryos, mRNA of Flag-tagged *Xenopus* Biglycan (Flag-$xBgn$) was microinjected alone or together with $xHtrA1$ into each blastomere of four-cell stage embryos. In addition, control-MO or $xHtrA1$-MO was microinjected into all blastomeres at the two-cell stage, followed by another injection of $xHtrA1$ mRNA into all blastomeres at the four-cell stage. When the control embryos reached mid-neurula stage, total proteins were extracted, fractionated on 12% SDS-PAGE gel, and subjected to Western blot analysis with an anti-Flag antibody. In *Xenopus* embryos, microinjection of $xHtrA1$ mRNA decreased the protein levels of Flag-$xBgn$. In contrast, $xHtrA1$-MO but not control-MO, led to the accumulation of the
full-length Flag-xBgn. It is of interest that the low molecular weight band at 55 kD in uninjected or control-MO-injected embryos disappeared in xHtrA1-MO-injected embryos, suggesting that this xBgn fragment may arise through proteolysis by endogenous xHtrA1 (Fig. 16B). This result shows that exogenously applied as well as endogenous xHtrA1 cleaves xBgn in vivo. We also observed that injected xHtrA1 mRNA degraded Flag-xSyn4 (Fig. 16C). Overexpression of xHtrA1 did not appear to affect xGpn4-Flag, but xHtrA1-MO led to an accumulation of this protein in the embryo (Fig. 16D), indicating that endogenous xHtrA1 may largely degrade xGpn4-Flag. Together, the results suggest that xBgn, xSyn4 and xGpn4 are proteolytic targets of xHtrA1 activity.

Biglycan contains one or two dermatan/chondroitin sulfate chains that are covalently linked to the core protein (Trowbridge and Gallo, 2002). Dermatan sulfate arises from chondroitin sulfate through epimerization of glucuronic into iduronic acid (Maccarana et al., 2006). As dermatan sulfate, but not chondroitin sulfate, binds to and activates FGF ligands (Taylor et al., 2005), we assessed the nature of the glycosaminoglycan in xBgn in Xenopus embryos. Flag-tagged xBgn was injected into Xenopus embryos, all glycosylated proteins were extracted from late neurula stage embryos and purified using an anion-exchange column. Treatment of purified proteoglycans with Chondroitinase B, which specifically degrades DS sugar chains, caused a mobility shift of Flag-tagged Biglycan (Fig. 16E), strongly indicating the presence of dermatan sulfate chains in Xenopus Biglycan.
Figure 16. xHtrA1 causes proteolytic cleavage of *Xenopus* Biglycan, Syndecan4 and Glypican4
(A) HEK293 cells in 6-well plate were transfected with 3 µg Flag-tagged proteoglycan substrates including Flag-xBgn, Flag-xSyn4 and xGpn4-Flag, either alone or together with 2.5 µg xHtrA1. The cell medium was exchanged to serum-free conditioning medium after one day, cells were harvested three days after transfection and lysed in RIPA buffer. The cell lysates were separated by 12% SDS-PAGE gel. Western blot analysis was done with anti-Flag antibody (upper panel). After stripping, the same membrane was probed with anti-xHtrA1 antibody (middle panel), and after another round of stripping, probed with anti α-Tubulin antibody (lower panel). xHtrA1 specifically cleaves Flag-tagged xBgn (lanes 2,3), Flag-xSyn4 (lanes 5,6) and xGpn4-Flag (Lanes 7,8). (B) *Xenopus* embryos injected with *Flag-tagged xBgn* mRNA (500 pg) alone or together with xHtrA1 mRNA (300 pg) into four-cell stage embryos. Embryos were harvested at stage 14 and proteins extracted and separated by 12% SDS-PAGE. Ponceau red staining was used as loading control. (C,D) *Xenopus* embryos were injected at the two-cell stage with control-MO or xHtrA1-MO (8 pmol per embryo) and at the four-cell stage with Flag-xSyn4 (150 pg), xGpn4-Flag (60 pg) or xHtrA1 mRNA (180 pg). Injected embryos were harvested at stage 20 and subjected to Western blot analysis. (E) *Flag-xBgn* mRNA (100 pg) was injected at the four-cell stage and embryos harvested at stage 22. Extraction of proteoglycans, anion-exchange purification and treatment with Chondroitinase B were kindly performed by Dr. Marco Maccarana (Univ. Lund).

3.17 Heparan sulfate and dermatan sulfate induce posteriorization, mesoderm and neuronal differentiation in an FGF-dependent manner
Biglycan contains 1-2 dermatan sulfate (DS) chains that are released upon digestion of the protein core (Trowbridge and Gallo, 2002), Syndecan4 and Glypican4 contain heparan
We compared the biological activities of exogenously added heparan sulfate (HS), dermatan sulfate (DS), and the chondroitin sulfates CSE and CSA in early *Xenopus* embryos. DS contains a high proportion of iduronic acid, which is absent in chondroitin sulfates (Trowbridge and Gallo, 2002). CSE has additional 6-O-sulfate compared with CSA. Upon injection into the blastocoel, HS caused loss of head structures (Fig. 17a,b). Likewise, DS at a hundred-fold higher dose resulted in anencephaly and occasional induction of secondary tails (Fig. 17c). In contrast, CSE had little and CSA no effect on head development and failed to induce ectopic tail-like structures (Fig. 17d,e). Importantly, defects in head development were reversed when embryos had been injected with *XFD* mRNA (Fig. 17a'-e'), indicating that the posteriorizing effect of polysaccharides depends on a functional FGF receptor. In addition, HS and DS, but not CSE and CSA, caused robust expansion of the mesodermal marker *Xbra* (Fig. 17f-j). While HS strongly induced ectopic neurons, DS, CSE and CSA only moderately expanded the neuronal marker *N-tubulin* expression territory (Fig. 17 k-o). *XFD* and *DnFGFR4* mRNA obscured ectopic mesoderm induction and neuronal differentiation, respectively (Fig. 17f'-j', k'-o'), indicating that the glycosaminoglycans require an intact FGF signaling pathway to exert their activities. These effects are strikingly similar to those induced by FGF signals (Fig. 12) and by xHtrA1 (Fig. 13), suggesting a functional interaction between HS, DS, xHtrA1, and FGF.
Figure 17. Heparan sulfate and dermatan sulfate induce posteriorization, mesoderm and neuronal differentiation in an FGF-dependent manner

(a-c) Heparan sulfate (HS, 30 ng), dermatan sulfate (DS, 3000 ng), and the chondroitin sulfates CSE and CSA (each 3000 ng) were injected into the blastocoel at stage 8 embryos. Note the loss or reduction of head structures by HS, DS and CSE, and the induction of an ectopic tail-like outgrowth by DS (arrowhead). (a’-e’) Injection of 110 pg XFD mRNA at the four-cell stage reverts the posteriorizing effects of HS, DS and CSE. (f-j) HS and DS injected at stage 6.5 significantly expand Xbra expression. (f’-j’) Expansion of Xbra by polysaccharides is blocked by injection of 220 pg XFD mRNA into the four-cell stage embryos. (k-o) HS, DS, CSE, and CSA injected into the blastocoel cavity at stage 8 expand N-tubulin expression. Note that HS significantly induces ectopic N-tubulin, whereas DS, CSE and CSA only mildly expand N-tubulin expression. (k’-o’) Microinjection of 110 pg DnFGFR4a mRNA blocks N-tubulin expansion caused by polysaccharides. Frequency of embryos with the indicated phenotype was: b, 63/63; c, 98/110 (anencephaly) and 20/110 (ectopic tail); d, 47/47; e, 53/53; b’, 11/11; c’, 7/7; d’, 5/6; e’, 9/13; g, 29/30; h, 30/40; i, 10/20 with slight expansion of Xbra; j, 9/9; g’, 46/46; h’, 25/37; i’, 50/50; j’, 43/43; l, 63/63; m, 14/21; n, 32/36 with slight expansion; o, 27/34 with slight expansion; l’, 22/22; m’, 9/17; n’, 35/35; o’, 16/17.
4. **Discussion**

In this study, we characterize the secreted serine protease HtrA1 in the *Xenopus* embryo. Microinjection of *xHtrA1* mRNA resulted in the loss of head tissue and induction of ectopic tail-like structures. Apart from patterning the anteroposterior axis, *xHtrA1* affects additional important processes, including mesoderm induction, dorsoventral patterning of the ectoderm, neuronal differentiation, regulation of the cell motility and proliferation. Using specific morpholino oligonucleotides or neutralizing antibodies against xHtrA1, we show that this protease plays an important role in proper head and tail development, mesoderm induction and neuronal differentiation. Importantly, *xHtrA1* is transcriptionally activated by *FGF8* and *FGF4*, cooperates with FGF signals to activate mesoderm markers, and the activity of xHtrA1 depends on an intact FGF signaling pathway.

4.1 **Interaction with IGF and BMP antagonism are not sufficient to explain the activities of xHtrA1**

The presence of an aminoterminal IGF binding domain in the HtrA1 protein (Fig. 1; Hou, 2004) suggests a possible interaction with insulin-like growth factor (IGF) signals. It has been suggested that HtrA1 may regulate the availability of the IGFs by cleaving IGF binding proteins (Zumbrunn and Trueb, 1996). Indeed, a recent study has shown that purified human HtrA1 protein modulates Insulin-like growth factor (IGF) signalling by cleaving the IGFBP5, (IGF binding protein 5; Hou et al., 2005). In *Xenopus* embryos, overexpressing IGFBP5 phenocopies IGFs to promote anterior neural structures (Pera et al., 2001). Hence, one may speculate that by cleaving IGFBP5, xHtrA1 may attenuate IGF signals. Downregulation of IGF signaling suppresses head development (Pera et al., 2001; Richard-Parpaillon et al., 2002), reminiscent of the anencephaly that results from *xHtrA1* mRNA injection (Fig. 4; Hou, 2004). However, the dorsalization of the ectoderm, induction of neuronal differentiation and stimulation of cell proliferation by *xHtrA1* (Fig. 8; Hou, 2004 and Fig.9) are characteristic for an activation of IGF signaling (Pera et al., 2001; 2003; Richard-Parpaillon et al., 2002). One way to reconcile the findings is to assume that xHtrA1 may function as a positive or negative regulator of IGF signaling in a context-dependent manner. However, the induction of secondary tail structures by xHtrA1 (Fig. 4; Hou, 2004) cannot be explained by either positive or negative regulation of IGF signals.
Previous studies in the mouse showed that HtrA1 binds to a wide range of TGFβ family proteins including BMP4, TGFβ1, TGFβ2, activin and GDF5, and blocks the activity of BMP4 and TGFβ1 in cell culture experiments (Oka et al., 2004). The dorsalization of ectoderm by xHtrA1, e.g. the expansion of the neural plate at the expense of neural crest and epidermis tissue, together with ectopic neuronal differentiation by xHtrA1 (Fig. 8; Hou, 2004) is consistent with inhibition of BMP signals. Soluble antagonists of BMP ligands, such as Chordin, Noggin and Follistatin, similarly dorsalize the ectoderm and promote neural development (De Robertis and Kuroda, 2004). However, other effects of xHtrA1 observed in Xenopus embryos cannot be explained by inhibition of TGFβ or BMP signaling. First, xHtrA1 eliminates anterior neural markers including Otx2, BF1, Rx2a, when injected into whole embryos (Fig. 6; Hou, 2004). Whereas inhibition of the BMP pathway, e.g. by Chordin, promotes anterior neural marker gene expression (Sasai et al., 1994, 1995). Second, xHtrA1 robustly expands the posterior expression domain of Sizzled (Fig. 6L; Hou, 2004). The BMP antagonist Chordin downregulates Sizzled expression. In contrast, elevation of BMP signals by knockdown of Chordin protein synthesis or overexpression of the metalloprotease Xolloid-related protein (Xlr), upregulates Sizzled gene activity (Lee et al., 2006). Third, xHtrA1 stimulates mesoderm development (Fig. 6D; Hou, 2004, Fig. 12H). However, blocking the TGFβ pathway, e.g. by dominant negative activin receptor or Nodal inhibitor Cerberus-short, impairs with mesoderm formation (Clements et al., 1999; Agius et al., 2000). Hence, anti-TGFβ activity does not account for the positive effect of xHtrA1 on mesoderm development. Indeed, active BMP or TGFβ signals lead to ectopic mesoderm formation (Dale et al., 1992; Hemmati-Brivanlou and Thomsen, 1995). Fourth, the induction of ectopic tail-like structures by xHtrA1 (Fig. 4; Hou, 2004) cannot be explained by antagonism of BMP, as secondary axes induced by BMP antagonists only contain trunk and head structures (Glinka et al, 1997). Several lines of evidence argue instead for an active role of BMP signaling in tail development. Ectopic expression of BMP4, a constitutively active BMP receptor, or an activated form of the BMP signaling intermediate Smad5 in the posterior neural plate of an early Xenopus neurula results in the formation of extra tail-like structures (Beck et al., 2001). Reduced BMP signaling, caused by e.g. injection of morpholino oligonucleotides against BMP7 and Twisted gastrulation, leads to a loss of posterior ventral mesoderm and truncation of tail structures (Zakin et al., 2005). In the mouse mutant, depletion of BMP signals impairs tail development (Winnier et al, 1995). Hence BMP signaling is both
necessary and sufficient for tail outgrowth in vertebrates. Fifth, Oka and co-workers showed that mouse mutant HtrA1 construct that carries a point mutation, in which catalytic serine residue is substituted with alanine, still binds to and attenuates TGFβ signals in cell culture assays. In *Xenopus*, blocking of TGFβ signaling suppresses mesoderm development (Clements et al., 1999) and blocking BMP signals promotes neural development (De Robertis and Kuroka, 2004). However, similar xHtrA1 mutant xHtrA1S307A did not show phenotypic effect in mRNA-injected *Xenopus* embryos and failed to suppress the mesodermal marker Xbra and expand the neural marker Sox2 (data not shown). Taken together, BMP antagonism is not sufficient to explain the activities of xHtrA1 during *Xenopus* embryonic development.

### 4.2 xHtrA1 is a novel regulator of FGF signaling

Several lines of evidence from our study support a specific link between xHtrA1 and FGF signaling in *Xenopus* embryonic development. The early expression pattern of xHtrA1 (Fig. 2) overlaps with known sites of FGF activity, as revealed by the transcription of crucial components of the FGF signaling pathway, including *FGF8* (Christen and Slack, 1997), *XFLRT3* (Böttcher et al., 2004), *Sef* (Fürthauer et al., 2002; Tsang et al., 2002) and *Sprouties* (Fürthauer et al., 2001, 2004), and the phosphorylation of the extracellular signal-regulated protein kinase (dpERK; Christen and Slack, 1999). Common expression was observed in the blastopore ring, posterior mesoderm, anterior neural plate, midbrain-hindbrain boundary, neural fold, and branchial arch region. It has been suggested that genes sharing expression sites form a synexpression group and as such may functionally interrelate (Niehrs and Meinhardt, 2002). Microinjection of *FGF8* and *FGF4* into ectoderm explants activates *de novo* expression of xHtrA1, although interference of FGF signaling through dominant negative FGF receptors does not reduce xHtrA1 transcripts in marginal zone explants (Fig. 3). This indicates that FGF signals are sufficient, but not required for the induction of xHtrA1. Thus, xHtrA1 is a FGF target gene that like *Sprouties*, *Sef* and *XFLRT3*, is expressed in response to FGF signaling (Fürthauer et al., 2001, 2002, 2004; Tsang et al., 2002; Böttcher et al., 2004). xHtrA1 and FGF signals have several common activities. First, anencephaly and ectopic tail-like structures, as induced by xHtrA1 mRNA injection (Figs. 4,12), have also been observed after misexpression of FGF ligands or signaling intermediates of the FGF-MAPK pathway. Microinjection of *FGF4* DNA or mRNAs encoding a constitutively active FGFR1, activated Ras, the
transmembrane protein XFLRT3, the Src-family kinase Laloo, or the Ets-type transcription factor ER81 induce microcephaly and ectopic tail-like structures (Isaacs et al., 1994; Pownall et al., 1996; Weinstein et al., 1998; Chen et al., 1999; Böttcher et al., 2004). Overexpression of FGF8 also leads to reduction of anterior structures, a trunk bent to the ventral side and an expanded proctodeum (Christen and Slack, 1997), reminiscent of the phenotype induced by xHtrA1 (Fig. 4; Hou, 2004). Second, like FGF signals (Pownall et al., 1996; Umbhauer et al., 2000; Liu et al., 2001; Bel-Vialar et al., 2002), xHtrA1 also acts as a posteriorizing agent for the central nervous system (Fig. 7). In mRNA-injected neural plate explants, xHtrA1 suppresses rostral neural markers and enhances more caudal markers instead, e.g. in the anterior-most neural plate section, the gene expression of the eye marker Rx2a and forebrain marker Otx2 was reduced, whereas the hindbrain marker Krox20 and the posterior hindbrain/spinal cord marker HoxD1 was induced upon microinjection of a low dose of xHtrA1 mRNA (Fig. 7). When a higher dose of xHtrA1 mRNA was injected, the expression of rostral neural markers including Krox20 were even completely erased in whole embryos (Fig. 6; Hou, 2004). Third, xHtrA1 stimulates mesoderm development, as shown by the formation of secondary notochord and somite tissue in mRNA-injected embryos (Fig. 4; Hou, 2004), expansion of the pan-mesodermal marker Xbra from the marginal zone into the animal hemisphere (Fig. 6; Hou, 2004), and de novo-induction of the mesodermal marker genes Xbra and Xcad3 in isolated animal cap explants (Fig. 12). Mesoderm induction is also caused by overexpression of FGF4 (Isaacs et al., 1994) and other activators of FGF/MAPK signaling (Pownall et al., 1996; Weinstein et al., 1998; Böttcher et al., 2004). Fourth, xHtrA1 markedly expands the neural plate at the expense of neural crest and epidermal tissue, and stimulates neuronal differentiation (Fig. 8; Hou, 2004), a phenotype that also results from misexpression of FGF8 (Hardcastle et al., 2000; Pera et al., 2003). Previous studies in chick, zebrafish and Xenopus have shown that FGFs, through the control of BMP activity, affect dorsoventral patterning in the ectoderm. FGF/MAPK signaling promotes the induction of neural fate by inhibiting BMP gene expression (Wilson et al., 2000; Fürthauer et al., 2004) or by phosphorylating and inactivating the BMP signaling intermediate Smad1 (Pera et al., 2003; Kuroda and De Robertis, 2004). Fifth, HtrA1 perturbs convergence-extension movements of the neural plate (Fig. 9). In Xenopus, the chick and the mouse, FGF signaling has been shown to directly affect morphogenetic cell movements during gastrulation (Ciruna et al., 1997; Nutt et al., 2001; Yang et al., 2002) through a mechanism that is distinct from the
Ras/MAPK pathway and depends on PLC-γ activation (Sivak et al., 2005). Sixth, xHtrA1 causes excessive cell proliferation (Fig. 9), as also observed upon activation of FGF signaling (Powers et al., 2000). In sum, the abnormalities caused by xHtrA1 are indistinguishable from those caused by FGF signals, strongly suggesting that xHtrA1 may act through activating FGF signaling.

Moreover, loss-of-function experiments suggest that xHtrA1 and FGF may share common functions. Knockdown of xHtrA1 by microinjection of specific morpholino oligonucleotides or of a neutralizing antibody resulted in enlarged head structures, reduced tail formation and deficient mesoderm development (Fig. 10 and data not shown). This phenotype also arises after injecting molecules that disrupt FGF/MAPK signaling, including a dominant negative FGF receptor (Amaya et al., 1991), a dominant negative Raf1 mutant (MacNicol et al., 1993), a MAPK-specific phosphatase (Umbhauer et al., 1995), a dominant-inhibitory Laloo mutant (Weinstein et al., 1998), or the FGF/MAPK antagonist Sef (Tsang et al., 2002). Microinjection of xHtrA1-MO also blocked expression of the differentiated neuron marker N-tubulin (Fig. 10), which also results from misexpression of DnFGFR4a, a dominant negative FGF receptor that mediates FGF8 signaling (Hardcastle et al., 2000). Downregulation of xHtrA1 eliminated phosphorylation and activation of the MAPK pathway intermediate ERK in whole embryos (Fig. 14), which is also observed in dissociated animal cap explants treated with the MEK inhibitor U0126 (Kuroda et al., 2005). These loss-of-function data indicate that xHtrA1 may play a role in allowing FGFs to signal.

Our animal cap explants experiment shows that xHtrA1 cooperates with FGF4 to induce mesoderm markers (Fig. 12), supporting the view that xHtrA1 may converge with the FGF signaling pathway. Abrogation of FGF signaling by injecting dominant negative FGF receptors blocks the posteriorization of the embryonic axis, induction of mesoderm and stimulation of neuronal differentiation caused by xHtrA1 (Fig. 13). This epistatic experiment shows that xHtrA1-mediated activities rely on intact FGF signaling. Importantly, xHtrA1 induced ectopic activation of the FGF signaling intermediate MAPK/ERK and induction of FGF4 and FGF8 expression (Fig. 14), suggesting that xHtrA1 acts upstream of FGF signals and is able to stimulate the FGF pathway in vivo. Our experiments indicate that xHtrA1 and FGF engage in a positive feedback loop, in
which FGF signals induce the transcription of \( xHtrA1 \) (Fig. 3), and vice versa, \( xHtrA1 \) transcriptionally activates FGF genes and promotes FGF signaling (Fig. 14). The autoinduction of positive and negative modulators is a recurring theme in growth factor signaling, and the FGF8 synexpression group provides a good example therefore (Niehrs and Meinhardt, 2002; Tsang and Dawid, 2004). The transmembrane protein XFLRT3, whose gene expression is activated by FGFs, binds to the FGF receptor at the cell surface and similarly as \( xHtrA1 \) stimulates FGF signalling (Böttcher et al., 2004). On the other hand, the membrane-bound Sef and cytosolic Sprouty and Spred proteins block the FGF pathway intracellularly and establish a negative feedback loop (Fuerthauer et al., 2002; Tsang et al., 2002; Sivak et al., 2005). Hence, \( xHtrA1 \) adds to an intricate network of feedback-regulated factors that modulates the activity of this important signaling pathway.

In *Xenopus*, FGF4 induces \( Xbra \) expression via the transcription factor Ets2 and, in turn, \( Xbra \) induces \( FGF4 \) expression (Isaacs et al., 1994; Kawachi et al., 2003). Our results suggest that \( xHtrA1 \) is integrated in this positive feed-forward network. It has been proposed that such a self-regulated biological signalling loop contributes to the establishment of local organizing centers (Tsang and Dawid, 2004). This system of regulation may explain how misexpression of \( xHtrA1 \), FGF4 or Ets-type transcription factors eventually leads to complex secondary tail-like outgrowths.

4.3 A model for the regulation of FGF signals in the extracellular space

FGF signaling is regulated at the cell surface and in the extracellular matrix by proteoglycans (PGs) of the heparan sulfate (HS) and dermatan sulfate (DS) families (Bernfield et al., 1999; Ornitz, 2000; Trowbridge and Gallo, 2002). Secreted FGFs tightly bind to HSPGs through interaction with their glycosaminoglycan (GAG) moieties. In this way, HSPGs restrict the diffusion of FGFs in the extracellular space. GAGs also stabilize the interaction of FGF with the FGF receptor, thereby increasing signal transduction. The protein core of the cell-associated HSPG is sensitive to degradation by a large spectrum of serine proteases, including chymotrypsin and trypsin. Cleavage at a labile region between the GAG attachment site and the membrane anchor releases the GAG-containing portion of HSPG from the cell surface (Rapraeger and Bernfield, 1985). Previous *in vitro* studies have shown that the secreted serine protease plasmin releases FGF2 that is bound to the extracellular matrix of cultured endothelial cells (Saksela and Rifkin, 1990). When released by plasmin, the growth factor is recovered from the medium as a complex with a
partly degraded HSPG. Interestingly, FGF2 is able to increase plasminogen activator activity in these cells, allowing for a positive feedback loop (Saksela et al., 1987).

In this study, we could show that xHtrA1 triggers the proteolytic cleavage of *Xenopus* Biglycan, Syndecan4 and Glypican4 in transfected cells and *Xenopus* embryos (Fig. 16). This finding supports a previous *in vitro* observation that identified bovine Biglycan as a substrate of N-terminally truncated mouse HtrA1 (Tocharus et al., 2004). It remains to be shown whether Syndecan4 or Glypican4 are directly cleaved by xHtrA1 or by other proteases that are activated by xHtrA1. To this end, purified xHtrA1 protein is needed to show *in vitro* proteolytic cleavage of isolated Syndecan4, and Glypican4 proteins. Interestingly, Glypican4 binds FGF2 and modulates FGF signaling in *Xenopus* (Galli et al., 2003), underscoring the notion that proteoglycans may mediate the stimulatory effect of xHtrA1 on FGF activity.

Using blastocoelic injections, we could demonstrate that HS and DS trigger posteriorization of the primary embryonic axis, mesoderm induction and neuronal differentiation (Fig. 17). Not only are the effects of heparan sulfate and dermatan sulfate reminiscent of those caused by FGF signals, but they also occur in an FGF-dependent manner. Interestingly, the biological potency of a given glycosaminoglycan (GAG) correlates with its reported affinity to FGFs. HS and DS, but not chondroitin sulfate, share a high content of iduronic acid, which renders conformational flexibility to the GAG chain and facilitates tight binding to FGF and its receptor (Trowbridge et al., 2002; Kramer and Yost, 2003). Previous *in vitro* studies have shown that DS binds to FGF2 and FGF7 and stimulate their activity during cellular proliferation (Penc et al., 1998; Trowbridge et al., 2002; Taylor et al., 2005). Our findings now strongly point towards an *in vivo* link between HS/DS and FGF signaling.

Based on these results, we propose a model that explains of how the secreted serine protease xHtrA1 may stimulate FGF signals in the extracellular space (Fig. 4.1). As FGFs have high affinities for GAG side-chains of proteoglycans, the FGFs are normally sequestered on or nearby to cells from which they are secreted, consistent with their function as short-range intercellular signaling molecules (Häcker et al., 2005; Bülow and Hobert, 2006). The secreted serine protease xHtrA1 triggers the cleavage of
proteoglycans, such as Biglycan, Syndecan4 and Glypican4, thereby releasing soluble FGF-GAG complexes. In this way, FGFs are able to reach cells far away from their site of synthesis and activate FGF receptors at distance. Since GAGs strengthen the binding of FGF ligands to their receptors, the FGF-GAG complexes also increase the overall signaling intensity.

Figure 4.1 Model for the stimulation of long-range FGF signaling by the secreted serine protease xHtrA1. xHtrA1 cleaves the protein moiety of proteoglycans and releases biologically active FGF bound to glycosaminoglycan (GAG). The FGF-GAG complex activates the FGF receptor on cells distant to its site of origin.

In support of this „proteolytic spread“ model, we could show that xHtrA1 has non-cell autonomous activity in the embryo. In lineage tracing experiments, we could show that molecular marker genes are induced in a non-cell autonomous manner (Fig. 8; Hou, 2004). Secondary tail-like structures arose on the ventral side although injected xHtrA1 mRNA is restricted to dorsal parts of the embryo (Fig. 4). Similarly, ectopic neuronal differentiation is induced on the contralateral side of xHtrA1 mRNA injection (Fig. 13). Using an animal cap conjugate experiment, we could demonstrate that xHtrA1 allows ectopic mesoderm induction far away from the source of FGF signals, indicating that xHtrA1 promotes long-range FGF signaling (Fig. 15).
In an attempt to demonstrate that xHtrA1 facilitates diffusion of FGF ligands in the extracellular space, we studied the distribution of exogenously added and fluorescently labeled FGFs in *Xenopus* embryonic explants using two different strategies. First, animal cap explants injected with FGF4-GFP/FGF8-GFP alone or in combination with xHtrA1 mRNA were juxtaposed to non-injected animal cap explants on coverslips and analysed by confocal microscopy. No clear difference could be observed between samples injected with or without xHtrA1 due to technical difficulties, including unequal distribution of injected mRNAs, release of FGF-GFP proteins during cutting and mounting of the explants and imperfect contact between explants in the conjugates. In addition, xHtrA1 may have caused the release of FGF-GFP ligands before explants were excised, leading to a relative decrease of FGF-GFP protein in xHtrA1-injected samples. In order to overcome these drawbacks, we used heparin beads soaked with Alex Fluor 488-labeled FGF8 protein and embedded them in the center of animal cap explants that were non-injected or injected with xHtrA1 mRNA. Confocal microscopy revealed that the signals within and around the beads were too weak to unambiguously trace the distribution of labeled FGF8 protein in explant tissues. Together, our confocal microscopy experiments do not allow to draw a conclusion about the diffusion of FGF signals in response to xHtrA1 treatment. However, the observation that xHtrA1 promotes the intensity and range of Xbra expression in FGF4 mRNA-injected animal cap conjugates clearly shows that xHtrA1 promotes long-range FGF signaling (Fig. 15).

### 4.4 Specificity of xHtrA1-mediated regulation of FGF signaling

HSPGs not only bind FGFs, but also other growth factors of the TGFβ and Wnt families (Iozzo 1998). Our model is consistent with the idea that xHtrA1 may also release and activate these factors. However, the activities and functions exhibited by xHtrA1 are most reminiscent of those shown by FGFs, supporting the interpretation that xHtrA1 predominantly activates FGF signaling in *Xenopus* embryos. One explanation could be that FGFs are probably unique in their requirement of HS for the ligand-receptor interaction (Rapraeger et al., 1991; Itoh and Sokol, 1994) and DS appears to interact with FGFs and their receptors (Penc et al., 1998; Trowbridge et al., 2002; Taylor et al., 2005).

The specific activation of FGF signaling in the embryo raises the question whether components of the FGF signaling pathway may be directly affected by xHtrA1? The
TGFα/EGF homologue Spitz in Drosophila is proteolytically activated by the serine protease Rhomboid-1 (Urban et al., 2001). Xenopus FGF3 has been reported to undergo proteolytic cleavage by the secreted serine protease plasmin to produce an N-terminally truncated product (Antoine et al., 2000). The processed 27 kD glycoprotein (gp27) has stronger biological activity than the full-length gp31 protein, as judged by their higher affinity to FGF receptors, enhanced ability to transform NIH3T3 cells and increased mitogenic activity. In addition, two aminoterminally processed isoforms of human FGF4 have higher affinity to FGF receptors and increased mitogenicity compared to the wild-type protein (Bellosa et al., 1993). It will be of interest to test whether xHtrA1 may process FGF ligands and render them hyperactive. Our preliminary results indicate that xHtrA1 appears to cleave Flag-tagged FGF4 protein in transfected HEK293 cells (data not shown).

4.5 Implication of HtrA1 for mammalian development and disease

Does the link between HtrA1 and FGF as reported here for the Xenopus embryo apply to other aspects of vertebrate development? During skeletal development, mouse HtrA1 overlaps with FGFs and their cognate receptors in precartilage condensations, ossification centers and the bone matrix (Oka et al., 2004; Ornitz, 2005). In addition to the previously described function of HtrA1 as regulator of TGFβ signaling (Oka et al., 2004), its co-localization with FGF signaling components suggests an additional link between HtrA1 and FGF during growth, differentiation and remodeling of bones. There are striking parallels between FGF signaling and proteoglycans in skeletal disease syndromes. For example, human hypochondroplasia can be caused by FGFR3 mutations (Ornitz, 2005) or by mutations in the Colony stimulating factor 1 receptor that prevent specific sulfation of GAG chains on proteoglycans (Hastbacka et al., 1994). Furthermore, a progeroid variant of the Ehlers-Danlos syndrome, characterized by short stature and skeletal malformations, results from mutations in the gene for galactosyltransferase-1 that lead to a selective loss of GAG synthesis of the dermal sulfate proteoglycans Biglycan and Decorin (Quentin et al., 1990). Biglycan is very abundant in bone, and Biglycan-deficient mice develop an osteoporosis-like phenotype suggesting an essential role in bone formation (Xu et al., 1998). HtrA is a major virulence factor of Streptococcus pneumoniae that induces inflammation in the lung (Ibrahim et al., 2004). FGFs participate in inflammation, repair and regeneration during wound healing (Powers et al., 2000), and dermatan sulfate is
highly enriched in wound fluids (Trowbridge and Gallo, 2002). Finally, age-related macular degeneration, which is the most common cause of blindness in aged people, is associated with upregulation of HtrA1 due to a promoter polymorphism (DeWan et al., 2006; Yang et al., 2006) and increased FGF gene expression (Kitaoka et al., 1997), suggesting a pathophysiological link for HtrA1 and angiogenic FGF signals in this eye neovascular disorder. Thus, our finding of a functional link between HtrA1, FGFs may not only be relevant to answer questions related to early development, but also contribute to understand other aspects including bone formation, wound repair and the etiology of a common cause of blindness.
5. Conclusion

In this study, we describe the secreted serine protease xHtrA1 as a novel positive modulator of FGF signaling. xHtrA1 contains an N-terminal signal peptide, an IGF binding domain, a Kazal-type serine protease inhibitor domain, a Trypsin-like serine protease domain and a PDZ domain. xHtrA1 is co-expressed with FGF8 at several sites, and its expression is activated by FGF signals. Microinjection of xHtrA1 mRNA into Xenopus embryos results in loss of head structures, induction of ectopic tails and expansion of mesoderm. xHtrA1 also enlarges the neural plate at the expense of neural crest and epidermal tissue and induced ectopic neurons. An analysis of mutant protein constructs indicates a crucial role of the proteolytic domain, the catalytic serine residue and the PDZ domain for the activity of xHtrA1. In loss-of-function experiments, an antisense morpholino oligonucleotide or a neutralizing antibody against xHtrA1 enlarges head structures and reduces tail development. xHtrA1-MO also impairs mesoderm formation and neuronal differentiation. In whole embryos, a dominant-negative FGF receptor (XFD) blocks the ability of xHtrA1 to inhibit head development, to induce secondary tails and to stimulate mesoderm formation. Moreover, a dominant-negative FGF receptor-4a (DnFGFR4a) impairs ectopic neuronal differentiation by xHtrA1, suggesting that xHtrA1 relies on intact FGF signaling pathway to exert its activities. xHtrA1 is sufficient and required for FGF/ERK signaling and activates the transcription of FGF4 and FGF8, suggesting a positive feedback regulation between xHtrA1 and FGF. xHtrA1 is shown to cleave the dermatan sulfate proteoglycan Biglycan and the heparan sulfate proteoglycans Syndecan4 and Glypican4. Blastocoelic injection of heparan sulfate and dermatan sulfate leads to posteriorization, ectopic mesoderm induction and neuronal differentiation in an FGF-dependent manner. Based on these experiments, a mechanism for the regulation of FGF by xHtrA1 is suggested. The secreted serine protease xHtrA1 cleaves proteoglycans such as Biglycan, Syndecan4 and Glypican4 and thereby releases FGF-glycosaminoglycan complexes, that allow long-range FGF signaling in a key inductive and morphogenetic phases of embryogenesis.
Bibliography


Nieuwkoop P. D. and Faber J. (1994) Normal table of Xenopus leavis (Daudin) A systematical and chronological survey of the development from the fertilized egg till the end of metamorphosis.


Curriculum Vitae

Name: Shirui Hou
Date of birth: Dec. 11, 1978
Place of birth: Beijing, P. R. China
Nationality: Chinese
Address: Lund Stem Cell Center,
BMC, B13, Klinikgatan 26,
S-22184 Lund, Sweden
Telephone: +46-46-22-23929
Fax: +46-46-22-20899
E-mail: conniehou@yahoo.com

Education
2007(expected) Ph.D, International MSc/Ph.D Molecular Biology Program,
Max Planck Research School,
Georg August University Goettingen, Germany
04/2004 MSc, International MSc/Ph.D Molecular Biology Program,
Max Planck Research School,
Department of Developmental Biochemistry, Georg August
University Goettingen, Germany
10/2002-10/2003 International MSc/Ph.D Molecular Biology program,
Max Planck Research School,
Georg August University Goettingen, Germany
06/2001 BSc, Department of Biology, College of Life Sciences,
Nankai University, Tianjin, China

Research Experience
11/2005-current Lund Strategic Research Center for Stem Cell Biology
and Cell Therapy, Lund, Sweden
Ph.D candidate
Supervisor: Dr. Edgar Pera
Project: Regulation of FGF signaling by proteolysis in the extracellular space

05/2004-11/2005 Department of Developmental Biochemistry, Georg August University Goettingen, Germany
Ph.D candidate
Supervisor: Dr. Edgar Pera and Prof. T. Pieler
Project: Regulation of FGF signaling by proteolysis in the extracellular space

10/2003-04/2004 Department of Developmental Biochemistry, Georg August University Goettingen, Germany
MSc candidate
Supervisor: Dr. Edgar Pera and Prof. T. Pieler
Master project: A secreted serine protease with IGF binding motif involved in anterior-posterior patterning of *Xenopus* embryos

11/2001-08/2002 Laboratory of Plant Biotechnology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
Research Assistant
Supervisor: Associate Prof. Xiaoying Chen
Project: Generation of transgenic rice using the agribacteria method

09/1997-06/2001 Department of Biology, College of Life Sciences, Nankai University, Tianjin, China
Supervisor: Prof. Qiang Chen
Project: The current status of biosensor and preparation of selective modified electrode
Awards and Fellowships

05/2004-03/2006 Georg Lichtenberg fellowship,
Ministry for Science and Culture of Lower Saxony, Germany
10/2002-08/2003 Stipend International Max Planck Research School
10/2000-06/2001 Procter & Gamble (P&G) Academic Scholarship
10/1998-10/2000 Academic Scholarship of Nankai University
1998 - 2001 All Excellent Student of Nankai University

Publications
